firstpost_date,url,trackback_author_nick,content,score,trackback_permalink,trackback_author_url
06/01/14,http://twitter.com/millennium_us/status/473087847361425408,millennium_us,"Phase 3 international, randomized study of patients with previously untreated mantle cell #lymsm presented at #ASCO14 http://t.co/OQcn2YFmkL",8.889687,http://twitter.com/millennium_US/status/473087847361425408,http://twitter.com/millennium_us
06/01/14,http://twitter.com/michaellampe/status/473088301055094784,michaellampe,"RT @millennium_US: Phase 3 international, randomized study of patients with previously untreated mantle cell #lymsm presented at #ASCO14 ht…",7.1810427,http://twitter.com/MichaelLampe/status/473088301055094784,http://twitter.com/michaellampe
06/01/14,http://twitter.com/drcbsteer/status/473090312005750784,drcbsteer,#ASCO14 Cavalli Mantle cell. PFS 24 vs 14 months with VR-CAP (V=bortezomib) HR 0.63 #lymsm,6.816539,http://twitter.com/drcbsteer/status/473090312005750784,http://twitter.com/drcbsteer
06/01/14,http://twitter.com/drcbsteer/status/473092991213907968,drcbsteer,"#ASCO14 SEXIE-R-CHOP14 study #lymsm ""elderly"" NHL. Higher dose rituximab given to male patients. 500mg/m2 No diff in rituximab rel toxicity",6.555351,http://twitter.com/drcbsteer/status/473092991213907968,http://twitter.com/drcbsteer
06/01/14,http://twitter.com/drcbsteer/status/473094662010699776,drcbsteer,#ASCO14 SEXIERCHOP14 study #lymsm 500 vs 375mg/m2 rituximab eliminated poorer outcomes seen in males vs females inRICOVER trial Pfreundschuh,10.661822,http://twitter.com/drcbsteer/status/473094662010699776,http://twitter.com/drcbsteer
06/01/14,http://twitter.com/mtmdphd/status/473095541149433856,mtmdphd,RT @drcbsteer: #ASCO14 SEXIERCHOP14 study #lymsm 500 vs 375mg/m2 rituximab eliminated poorer outcomes seen in males vs females inRICOVER tr…,9.805132,http://twitter.com/mtmdphd/status/473095541149433856,http://twitter.com/mtmdphd
06/01/14,http://twitter.com/drcbsteer/status/473096940977418240,drcbsteer,#ASCO14 #lymsm Pfreundschuh trial addressed the fact that rituximab dosing has been empiric until now and refining this can improve outcomes,7.0205245,http://twitter.com/drcbsteer/status/473096940977418240,http://twitter.com/drcbsteer
06/01/14,http://twitter.com/drcbsteer/status/473098685883371520,drcbsteer,#ASCO14 Question time - Pfreundschuh - 375mg/m2 rituximab may not be the standard dose in females either. We just don't know #lymsm,6.789653,http://twitter.com/drcbsteer/status/473098685883371520,http://twitter.com/drcbsteer
06/01/14,http://twitter.com/drcbsteer/status/473099537268371456,drcbsteer,#ASCO14 #lymsm Judith Trotman from Sydney presenting utility of PET-CT in follicular NHL  - Go Judith!,6.9115076,http://twitter.com/drcbsteer/status/473099537268371456,http://twitter.com/drcbsteer
06/01/14,http://twitter.com/mtmdphd/status/473099551084388353,mtmdphd,Trotman #lymsm #ASCO14 - PET in FL - Response assessment - FLIPI fail to ID all Px http://t.co/ImeTa1POJm,10.805806,http://twitter.com/mtmdphd/status/473099551084388353,http://twitter.com/mtmdphd
06/01/14,http://twitter.com/drcbsteer/status/473099844274634752,drcbsteer,RT @mtmdphd: Trotman #lymsm #ASCO14 - PET in FL - Response assessment - FLIPI fail to ID all Px http://t.co/ImeTa1POJm,6.8128233,http://twitter.com/drcbsteer/status/473099844274634752,http://twitter.com/drcbsteer
06/01/14,http://twitter.com/mtmdphd/status/473100007080722432,mtmdphd,Trotman Abstr 8502 #lymsm #ASCO14 - PET in FL - 3 studies http://t.co/3VVQbVs5Tn,10.905926,http://twitter.com/mtmdphd/status/473100007080722432,http://twitter.com/mtmdphd
06/01/14,http://twitter.com/mtmdphd/status/473100121593225217,mtmdphd,Trotman #lymsm #ASCO14 - PET in FL - Aim http://t.co/LR7n2nnfgE,11.162115,http://twitter.com/mtmdphd/status/473100121593225217,http://twitter.com/mtmdphd
06/01/14,http://twitter.com/mtmdphd/status/473100311708827650,mtmdphd,"Trotman #lymsm #ASCO14 - PET in FL - 5 Point Scale (5PS) - Meignan M, 2009 http://t.co/MwRspzoVoi",9.98679,http://twitter.com/mtmdphd/status/473100311708827650,http://twitter.com/mtmdphd
06/01/14,http://twitter.com/mtmdphd/status/473100474556481536,mtmdphd,Trotman #lymsm #ASCO14 - PET in FL - Study Population - n=246 Pts reviewed http://t.co/29la8OYVan,10.107891,http://twitter.com/mtmdphd/status/473100474556481536,http://twitter.com/mtmdphd
06/01/14,http://twitter.com/drcbsteer/status/473100489769635841,drcbsteer,Ah ha .... @mtmdphd has arrived in the #lymsm Lymphoma/plasma cell oral presentations - I can relax and read his tweets and photos. #ASCO14,7.904936,http://twitter.com/drcbsteer/status/473100489769635841,http://twitter.com/drcbsteer
06/01/14,http://twitter.com/drcbsteer/status/473100543507050496,drcbsteer,RT @mtmdphd: Trotman Abstr 8502 #lymsm #ASCO14 - PET in FL - 3 studies http://t.co/3VVQbVs5Tn,6.906358,http://twitter.com/drcbsteer/status/473100543507050496,http://twitter.com/drcbsteer
06/01/14,http://twitter.com/drcbsteer/status/473100562444353536,drcbsteer,RT @mtmdphd: Trotman #lymsm #ASCO14 - PET in FL - Aim http://t.co/LR7n2nnfgE,7.111377,http://twitter.com/drcbsteer/status/473100562444353536,http://twitter.com/drcbsteer
06/01/14,http://twitter.com/mtmdphd/status/473100861041016832,mtmdphd,Trotman #lymsm #ASCO14 - PET in FL - PFS according to CT response http://t.co/q93Qqq6Rym,11.026468,http://twitter.com/mtmdphd/status/473100861041016832,http://twitter.com/mtmdphd
06/01/14,http://twitter.com/mtmdphd/status/473101059670691840,mtmdphd,Trotman #lymsm #ASCO14 - PET in FL - Postinduction PET review concordance - 3 indep reviewers http://t.co/jOU28p6dp3,10.588838,http://twitter.com/mtmdphd/status/473101059670691840,http://twitter.com/mtmdphd
06/01/14,http://twitter.com/mtmdphd/status/473101249345515520,mtmdphd,Trotman #lymsm #ASCO14 - PET in FL - PET Review Results http://t.co/1eiRkdT62l,10.40117,http://twitter.com/mtmdphd/status/473101249345515520,http://twitter.com/mtmdphd
06/01/14,http://twitter.com/drcbsteer/status/473101312658505728,drcbsteer,RT @mtmdphd: Trotman #lymsm #ASCO14 - PET in FL - PFS according to CT response http://t.co/q93Qqq6Rym,7.027074,http://twitter.com/drcbsteer/status/473101312658505728,http://twitter.com/drcbsteer
06/01/14,http://twitter.com/drcbsteer/status/473101373441978368,drcbsteer,RT @mtmdphd: Trotman #lymsm #ASCO14 - PET in FL - Postinduction PET review concordance - 3 indep reviewers http://t.co/jOU28p6dp3,6.616596,http://twitter.com/drcbsteer/status/473101373441978368,http://twitter.com/drcbsteer
06/01/14,http://twitter.com/mtmdphd/status/473101498495148034,mtmdphd,Trotman #lymsm #ASCO14 - PET in FL - Both PET cut-offs predictive of PFS - HR 3.9 http://t.co/hCSeZ2hMpF,9.841081,http://twitter.com/mtmdphd/status/473101498495148034,http://twitter.com/mtmdphd
06/01/14,http://twitter.com/mtmdphd/status/473101667953422336,mtmdphd,Trotman #lymsm #ASCO14 - PET in FL - HR 6.7 for OS based on postinduction PET status http://t.co/DVRqEEYk4c,10.97158,http://twitter.com/mtmdphd/status/473101667953422336,http://twitter.com/mtmdphd
06/01/14,http://twitter.com/mtmdphd/status/473101973550424064,mtmdphd,"Trotman #lymsm #ASCO14 - PET in FL - With PET/CT, CT assessment limited value. 5PS new SOC",10.83813,http://twitter.com/mtmdphd/status/473101973550424064,http://twitter.com/mtmdphd
06/01/14,http://twitter.com/mtmdphd/status/473102165805121536,mtmdphd,Trotman #lymsm #ASCO14 - PET in FL - Postinduction PET-CT a platform to study response-adapted therapy. http://t.co/0SiBRS77wO,9.836594,http://twitter.com/mtmdphd/status/473102165805121536,http://twitter.com/mtmdphd
06/01/14,http://twitter.com/drcbsteer/status/473102166002253824,drcbsteer,RT @mtmdphd: Trotman #lymsm #ASCO14 - PET in FL - HR 6.7 for OS based on postinduction PET status http://t.co/DVRqEEYk4c,6.9062934,http://twitter.com/drcbsteer/status/473102166002253824,http://twitter.com/drcbsteer
06/01/14,http://twitter.com/mtmdphd/status/473102945182318592,mtmdphd,Casasnovas Abstr 8503 #lymsm #ASCO14 - Ph2 RCT R-ACVBP + BEAM/ASCT in high risk DLBCL - Vitolo Lugano Abs 072 http://t.co/LV2RTZ2vSs,10.214905,http://twitter.com/mtmdphd/status/473102945182318592,http://twitter.com/mtmdphd
06/01/14,http://twitter.com/mtmdphd/status/473103189500518400,mtmdphd,Casasnovas #lymsm #ASCO14 - Ph2 RCT R-ACVBP + BEAM/ASCT in high risk DLBCL - aaIPI 1 - R-ACVBP sup to RCHOP21 http://t.co/gATOWag36g,9.393143,http://twitter.com/mtmdphd/status/473103189500518400,http://twitter.com/mtmdphd
06/01/14,http://twitter.com/mtmdphd/status/473103304721825792,mtmdphd,Casasnovas #lymsm #ASCO14 - Ph2 RCT R-ACVBP + BEAM/ASCT in high risk DLBCL - aaIPI 2-3 - RCHOP14 similar to R-MegaCHOP inductions,9.327312,http://twitter.com/mtmdphd/status/473103304721825792,http://twitter.com/mtmdphd
06/01/14,http://twitter.com/drcbsteer/status/473103479712776192,drcbsteer,"RT @mtmdphd: Trotman #lymsm #ASCO14 - PET in FL - With PET/CT, CT assessment limited value. 5PS new SOC",6.844176,http://twitter.com/drcbsteer/status/473103479712776192,http://twitter.com/drcbsteer
06/01/14,http://twitter.com/mtmdphd/status/473103617449541633,mtmdphd,Casasnovas #lymsm #ASCO14 - Ph2 RCT R-ACVBP + BEAM/ASCT in high risk DLBCL - Study design... http://t.co/8bkuvidoKX,9.683696,http://twitter.com/mtmdphd/status/473103617449541633,http://twitter.com/mtmdphd
06/01/14,http://twitter.com/mtmdphd/status/473104160020525056,mtmdphd,Casasnovas #lymsm #ASCO14 - Ph2 RCT R-ACVBP + BEAM/ASCT in high risk DLBCL - Response after 4 cycles http://t.co/E4OacSnLs4,9.7401495,http://twitter.com/mtmdphd/status/473104160020525056,http://twitter.com/mtmdphd
06/01/14,http://twitter.com/mtmdphd/status/473104329818537984,mtmdphd,Casasnovas #lymsm #ASCO14 - Ph2 RCT R-ACVBP + BEAM/ASCT in high risk DLBCL - PET2 and PET4 results http://t.co/zE7tSAavmK,10.36247,http://twitter.com/mtmdphd/status/473104329818537984,http://twitter.com/mtmdphd
06/01/14,http://twitter.com/mtmdphd/status/473104653035790336,mtmdphd,Casasnovas #lymsm #ASCO14 - Ph2 RCT R-ACVBP + BEAM/ASCT in high risk DLBCL - PFS/OS similar http://t.co/wUwxUV8Bjk,10.471184,http://twitter.com/mtmdphd/status/473104653035790336,http://twitter.com/mtmdphd
06/01/14,http://twitter.com/mtmdphd/status/473104818899529728,mtmdphd,Casasnovas #lymsm #ASCO14 - Ph2 RCT R-ACVBP + BEAM/ASCT in high risk DLBCL - LNH 2007-3B Conclusions http://t.co/4bBQR2rYUF,10.358309,http://twitter.com/mtmdphd/status/473104818899529728,http://twitter.com/mtmdphd
06/01/14,http://twitter.com/sgiraltbmtdoc/status/473104848603193346,sgiraltbmtdoc,RT @mtmdphd: Casasnovas Abstr 8503 #lymsm #ASCO14 - Ph2 RCT R-ACVBP + BEAM/ASCT in high risk DLBCL - Vitolo Lugano Abs 072 http://t.co/LV2R…,6.241821,http://twitter.com/sgiraltbmtdoc/status/473104848603193346,http://twitter.com/sgiraltbmtdoc
06/01/14,http://twitter.com/mtmdphd/status/473105014953869312,mtmdphd,Casasnovas #lymsm #ASCO14 - Ph2 RCT R-ACVBP + BEAM/ASCT in high risk DLBCL - primary objective not reached. PET guided may equalize Tx's,9.495984,http://twitter.com/mtmdphd/status/473105014953869312,http://twitter.com/mtmdphd
06/01/14,http://twitter.com/mtmdphd/status/473105184030466048,mtmdphd,Casasnovas #lymsm #ASCO14 - Ph2 RCT R-ACVBP + BEAM/ASCT in high risk DLBCL - Outcomes http://t.co/NUeOnXKhOa,9.729045,http://twitter.com/mtmdphd/status/473105184030466048,http://twitter.com/mtmdphd
06/01/14,http://twitter.com/maurerstats/status/473105261645664256,maurerstats,RT @mtmdphd: Casasnovas #lymsm #ASCO14 - Ph2 RCT R-ACVBP + BEAM/ASCT in high risk DLBCL - LNH 2007-3B Conclusions http://t.co/4bBQR2rYUF,6.3910704,http://twitter.com/MaurerStats/status/473105261645664256,http://twitter.com/maurerstats
06/01/14,http://twitter.com/mtmdphd/status/473105414654275584,mtmdphd,Casasnovas #lymsm #ASCO14 - GAINED - GA In NEwly Diagnosed DLBCL &lt;- new trial http://t.co/2WaqPSzNhU,10.063069,http://twitter.com/mtmdphd/status/473105414654275584,http://twitter.com/mtmdphd
06/01/14,http://twitter.com/williamdale_md/status/473105614927712257,williamdale_md,RT @drcbsteer: Ah ha .... @mtmdphd has arrived in the #lymsm Lymphoma/plasma cell oral presentations - I can relax and read his tweets and …,6.9059687,http://twitter.com/WilliamDale_MD/status/473105614927712257,http://twitter.com/williamdale_md
06/01/14,http://twitter.com/mtmdphd/status/473105963193733122,mtmdphd,Kurtz #lymsm #ASCO14 - monitoring in DLBCL - Rationale &amp; Objective - circulating tumor DNA (ctDNA) http://t.co/MtCE0lixMe,11.082319,http://twitter.com/mtmdphd/status/473105963193733122,http://twitter.com/mtmdphd
06/01/14,http://twitter.com/mtmdphd/status/473106325363101696,mtmdphd,Kurtz #lymsm #ASCO14 - ctDNA monitoring in DLBCL - Ig genes detected by High Throughput Sequencing (IgHTS) http://t.co/l5Jugdt9aW,9.895092,http://twitter.com/mtmdphd/status/473106325363101696,http://twitter.com/mtmdphd
06/01/14,http://twitter.com/drzafergokgoz/status/473106477750956032,drzafergokgoz,RT @mtmdphd: Kurtz #lymsm #ASCO14 - monitoring in DLBCL - Rationale &amp; Objective - circulating tumor DNA (ctDNA) http://t.co/MtCE0lixMe,6.5017347,http://twitter.com/drzafergokgoz/status/473106477750956032,http://twitter.com/drzafergokgoz
06/01/14,http://twitter.com/mtmdphd/status/473106482716635136,mtmdphd,Kurtz #lymsm #ASCO14 - ctDNA monitoring in DLBCL - MRD - Molecular Residual Disease http://t.co/t35hzOz6bB,9.808597,http://twitter.com/mtmdphd/status/473106482716635136,http://twitter.com/mtmdphd
06/01/14,http://twitter.com/markaorourke/status/473106555869859840,markaorourke,RT @mtmdphd: Kurtz #lymsm #ASCO14 - monitoring in DLBCL - Rationale &amp; Objective - circulating tumor DNA (ctDNA) http://t.co/MtCE0lixMe,6.5017347,http://twitter.com/markaorourke/status/473106555869859840,http://twitter.com/markaorourke
06/01/14,http://twitter.com/mtmdphd/status/473106629043318785,mtmdphd,Kurtz #lymsm #ASCO14 - ctDNA monitoring in DLBCL - Methods - Stanford &amp; Australia http://t.co/F4r1mQRfZt,9.82198,http://twitter.com/mtmdphd/status/473106629043318785,http://twitter.com/mtmdphd
06/01/14,http://twitter.com/mtmdphd/status/473106802222329856,mtmdphd,Kurtz #lymsm #ASCO14 - ctDNA monitoring in DLBCL - Pt Characteristics http://t.co/zQ632bHrgB,10.139996,http://twitter.com/mtmdphd/status/473106802222329856,http://twitter.com/mtmdphd
06/01/14,http://twitter.com/mtmdphd/status/473107519645429760,mtmdphd,Kurtz #lymsm #ASCO14 - ctDNA monitoring in DLBCL - http://t.co/zSKqgQSNdj,10.243094,http://twitter.com/mtmdphd/status/473107519645429760,http://twitter.com/mtmdphd
06/01/14,http://twitter.com/mtmdphd/status/473107726667493377,mtmdphd,"Kurtz #lymsm #ASCO14 - ctDNA monitoring in DLBCL - MRD vs. PET-CT during Surveillance - 100% Spec, 100% PPV !! http://t.co/6ZF60EFjIs",9.605172,http://twitter.com/mtmdphd/status/473107726667493377,http://twitter.com/mtmdphd
06/01/14,http://twitter.com/mtmdphd/status/473107761333411840,mtmdphd,"Kurtz #lymsm #ASCO14 - ctDNA monitoring in DLBCL - 
(this is very cool)",10.867831,http://twitter.com/mtmdphd/status/473107761333411840,http://twitter.com/mtmdphd
06/01/14,http://twitter.com/mtmdphd/status/473107949100208128,mtmdphd,Kurtz #lymsm #ASCO14 - ctDNA monitoring in DLBCL - Sensitivity of MRD improves closer to relapse http://t.co/WhBITeFhzM,9.996946,http://twitter.com/mtmdphd/status/473107949100208128,http://twitter.com/mtmdphd
06/01/14,http://twitter.com/mtmdphd/status/473108487913111552,mtmdphd,"Kurtz #lymsm #ASCO14 - ctDNA monitoring in DLBCL - MRD Dynamics - Pt1 granuloma, Pt2 recurrent NHL - limitations http://t.co/2qI0CO5a6O",9.53781,http://twitter.com/mtmdphd/status/473108487913111552,http://twitter.com/mtmdphd
06/01/14,http://twitter.com/mtmdphd/status/473108621468135424,mtmdphd,Kurtz #lymsm #ASCO14 - ctDNA monitoring in DLBCL - Advantages and Disadvantages http://t.co/gMqNGJMQmf,10.076532,http://twitter.com/mtmdphd/status/473108621468135424,http://twitter.com/mtmdphd
06/01/14,http://twitter.com/mtmdphd/status/473108733246308352,mtmdphd,Kurtz #lymsm #ASCO14 - ctDNA monitoring in DLBCL - Conclusions http://t.co/IY32SslMtI,11.306142,http://twitter.com/mtmdphd/status/473108733246308352,http://twitter.com/mtmdphd
06/01/14,http://twitter.com/dmooneymd/status/473108989711241217,dmooneymd,IgHTS can detect molecular residual disease in DLBCL noninvasive through plasma and lymphocyte analysis. #lymsm #ASCO14,6.9113374,http://twitter.com/dmooneymd/status/473108989711241217,http://twitter.com/dmooneymd
06/01/14,http://twitter.com/mtmdphd/status/473109121982406657,mtmdphd,Flower #lymsm #ASCO14 - Disc - Note need quality PET scans for 5 Point Score (5PS) http://t.co/RwSP2qdl2p,10.290841,http://twitter.com/mtmdphd/status/473109121982406657,http://twitter.com/mtmdphd
06/01/14,http://twitter.com/dmooneymd/status/473111144824311808,dmooneymd,"Pet-directed therapy for high risk DLBCL is feasible, per cassanovas. Don't know if this led to improved outcomes, though. #lymsm #ASCO14",6.9530745,http://twitter.com/dmooneymd/status/473111144824311808,http://twitter.com/dmooneymd
06/01/14,http://twitter.com/dmooneymd/status/473111994963197952,dmooneymd,Flowers: Surveillance imaging in nhl-Scan only relapse detection is rare (1-3%) with low potential of secondary malignancies. #lymsm #ASCO14,10.597776,http://twitter.com/dmooneymd/status/473111994963197952,http://twitter.com/dmooneymd
06/01/14,http://twitter.com/mtmdphd/status/473112072046510080,mtmdphd,Flower #lymsm #ASCO14 - Disc - Alternatives to Surveillance Imaging http://t.co/KnvIdBFZjl,11.082308,http://twitter.com/mtmdphd/status/473112072046510080,http://twitter.com/mtmdphd
06/01/14,http://twitter.com/mtmdphd/status/473112416449220608,mtmdphd,Flower #lymsm #ASCO14 - Disc - Kurtz et al 8504 - IgHTS - provocative. Future studies to establish clin utility http://t.co/9AWGvAVUxC,10.45063,http://twitter.com/mtmdphd/status/473112416449220608,http://twitter.com/mtmdphd
06/01/14,http://twitter.com/dridimohamedali/status/473113650526683136,dridimohamedali,RT @mtmdphd: Flower #lymsm #ASCO14 - Disc - Kurtz et al 8504 - IgHTS - provocative. Future studies to establish clin utility http://t.co/9A…,6.4804044,http://twitter.com/Dridimohamedali/status/473113650526683136,http://twitter.com/dridimohamedali
06/01/14,http://twitter.com/mtmdphd/status/473114579518906368,mtmdphd,#lymsm #ASCO14 commenter - try using CT texture analysis as another imaging modality,10.411955,http://twitter.com/mtmdphd/status/473114579518906368,http://twitter.com/mtmdphd
06/01/14,http://twitter.com/mtmdphd/status/473115905309016065,mtmdphd,Forero-Torres #lymsm #ASCO14 - Ph1 SGN-CD19A in rel/ref NHL - interim analysis http://t.co/ZkDegSRvMu,10.558125,http://twitter.com/mtmdphd/status/473115905309016065,http://twitter.com/mtmdphd
06/01/14,http://twitter.com/mtmdphd/status/473116099366887425,mtmdphd,Forero-Torres #lymsm #ASCO14 - SGN-CD19A Targeted to B-cell Malignancies - CD19 is most expressed Ag in B-cell CA http://t.co/B5knKlvAEj,10.227799,http://twitter.com/mtmdphd/status/473116099366887425,http://twitter.com/mtmdphd
06/01/14,http://twitter.com/mtmdphd/status/473116284356677632,mtmdphd,Forero-Torres #lymsm #ASCO14 - SGN-CD19A in rel/ref NHL - Proposed Mechanism of Action http://t.co/MNveUd4E78,9.821591,http://twitter.com/mtmdphd/status/473116284356677632,http://twitter.com/mtmdphd
06/01/14,http://twitter.com/mtmdphd/status/473116357203333120,mtmdphd,Forero-Torres #lymsm #ASCO14 - SGN-CD19A in rel/ref NHL - humanized anti-CD19 monoclonal Ab,9.5831585,http://twitter.com/mtmdphd/status/473116357203333120,http://twitter.com/mtmdphd
06/01/14,http://twitter.com/drmarkham/status/473116399507087361,drmarkham,RT @dmooneymd: Flowers: Surveillance imaging in nhl-Scan only relapse detection is rare (1-3%) with low potential of secondary malignancies…,9.796096,http://twitter.com/DrMarkham/status/473116399507087361,http://twitter.com/drmarkham
06/01/14,http://twitter.com/mtmdphd/status/473116607951413248,mtmdphd,Forero-Torres #lymsm #ASCO14 - SGN-CD19A in rel/ref NHL - Objectives and Eligibility Criteria http://t.co/DnM9vhTY19,9.745171,http://twitter.com/mtmdphd/status/473116607951413248,http://twitter.com/mtmdphd
06/01/14,http://twitter.com/mtmdphd/status/473116787220156416,mtmdphd,Forero-Torres #lymsm #ASCO14 - SGN-CD19A in rel/ref NHL - Study Design http://t.co/ZtbUQYLTtJ,9.89154,http://twitter.com/mtmdphd/status/473116787220156416,http://twitter.com/mtmdphd
06/01/14,http://twitter.com/mtmdphd/status/473116996801150976,mtmdphd,"Forero-Torres #lymsm #ASCO14 - SGN-CD19A rel/ref NHL - Study Status - no DLT in cycle 1. Doses 3, 4, 5 mg/kg expanded http://t.co/l8gEMrPQlY",9.620752,http://twitter.com/mtmdphd/status/473116996801150976,http://twitter.com/mtmdphd
06/01/14,http://twitter.com/mtmdphd/status/473117148207124480,mtmdphd,Forero-Torres #lymsm #ASCO14 - SGN-CD19A in rel/ref NHL - (so far) Pt and disease characteristics http://t.co/CJ4jLUuFrb,9.7588415,http://twitter.com/mtmdphd/status/473117148207124480,http://twitter.com/mtmdphd
06/01/14,http://twitter.com/mtmdphd/status/473117386493939712,mtmdphd,Forero-Torres #lymsm #ASCO14 - SGN-CD19A in rel/ref NHL - AE in &gt;= 15% Pts http://t.co/CjRutcCmj4,9.8353615,http://twitter.com/mtmdphd/status/473117386493939712,http://twitter.com/mtmdphd
06/01/14,http://twitter.com/mtmdphd/status/473117482048577536,mtmdphd,"Forero-Torres #lymsm #ASCO14 - SGN-CD19A in rel/ref NHL - blurred vision, keratopathy, TCP, anemia - gr &gt;= 3 AEs in &gt;= 2 pts",9.547198,http://twitter.com/mtmdphd/status/473117482048577536,http://twitter.com/mtmdphd
06/01/14,http://twitter.com/mtmdphd/status/473117729890000896,mtmdphd,Forero-Torres #lymsm #ASCO14 - SGN-CD19A in rel/ref NHL - Superficial Microcystic Keratopathy #OphthoOncology http://t.co/3YIQYniAiJ,9.53781,http://twitter.com/mtmdphd/status/473117729890000896,http://twitter.com/mtmdphd
06/01/14,http://twitter.com/mtmdphd/status/473118047721750528,mtmdphd,Forero-Torres #lymsm #ASCO14 - SGN-CD19A in rel/ref NHL - 84% eye toxicity - most grade 1/2. Symptoms reversible http://t.co/lwH3DmMVh6,10.777909,http://twitter.com/mtmdphd/status/473118047721750528,http://twitter.com/mtmdphd
06/01/14,http://twitter.com/mtmdphd/status/473118123550584832,mtmdphd,Forero-Torres #lymsm #ASCO14 - SGN-CD19A in rel/ref NHL - steroids and dose mods help for eye sx. #OphthOncology,9.739719,http://twitter.com/mtmdphd/status/473118123550584832,http://twitter.com/mtmdphd
06/01/14,http://twitter.com/mtmdphd/status/473118204534214656,mtmdphd,Forero-Torres #lymsm #ASCO14 - SGN-CD19A in rel/ref NHL - prophylactic steroids is under evaluation - SMK,10.413093,http://twitter.com/mtmdphd/status/473118204534214656,http://twitter.com/mtmdphd
06/01/14,http://twitter.com/mtmdphd/status/473118406410260481,mtmdphd,Forero-Torres #lymsm #ASCO14 - SGN-CD19A in rel/ref NHL - Pharmocokinetics (PK) - ~2 week half-life http://t.co/6IO2qbMM1u,9.635267,http://twitter.com/mtmdphd/status/473118406410260481,http://twitter.com/mtmdphd
06/01/14,http://twitter.com/mtmdphd/status/473118542112755712,mtmdphd,Forero-Torres #lymsm #ASCO14 - SGN-CD19A in rel/ref NHL - Best Clinical Response (per Investigator) http://t.co/eqlS0KAY6z,9.816075,http://twitter.com/mtmdphd/status/473118542112755712,http://twitter.com/mtmdphd
06/01/14,http://twitter.com/mtmdphd/status/473118674581463040,mtmdphd,Forero-Torres #lymsm #ASCO14 - SGN-CD19A in rel/ref NHL - Waterfall plot (about 1/4 of PR still on Tx) http://t.co/3IhttyTo5H,10.999069,http://twitter.com/mtmdphd/status/473118674581463040,http://twitter.com/mtmdphd
06/01/14,http://twitter.com/dmooneymd/status/473118700321529857,dmooneymd,"Forero: Phase I sgn-cd19a (antibody drug conjugate) in refractory nhl. Ae of keratopathy. 16% cr, 14%pr. 24% still tx. #lymsm #ASCO14 #uab",6.4207907,http://twitter.com/dmooneymd/status/473118700321529857,http://twitter.com/dmooneymd
06/01/14,http://twitter.com/mtmdphd/status/473118776234622976,mtmdphd,Forero-Torres #lymsm #ASCO14 - SGN-CD19A in rel/ref NHL - http://t.co/aPjSru3IIN,9.867967,http://twitter.com/mtmdphd/status/473118776234622976,http://twitter.com/mtmdphd
06/01/14,http://twitter.com/mtmdphd/status/473119010457137152,mtmdphd,"Forero-Torres #lymsm #ASCO14 - SGN-CD19A in rel/ref NHL - Conclusions - ORR 30% (11/37), CR 16%, eye gtt, encouraging http://t.co/sJLPjAGNd2",10.895227,http://twitter.com/mtmdphd/status/473119010457137152,http://twitter.com/mtmdphd
06/01/14,http://twitter.com/vincentrk/status/473119156368207872,vincentrk,Very impressive. MT “@mtmdphd: Forero-Torres #lymsm #ASCO14 - SGN-CD19A in rel/ref NHL (about 1/4 of PR still on Tx) http://t.co/Yaf46uLaiI”,11.779381,http://twitter.com/VincentRK/status/473119156368207872,http://twitter.com/vincentrk
06/01/14,http://twitter.com/mtmdphd/status/473119175997923328,mtmdphd,Forero-Torres #lymsm #ASCO14 - SGN-CD19A in rel/ref NHL - Time to ramp up the #OphthoOncology clinics... http://t.co/Fz8ibjAQyl,9.742922,http://twitter.com/mtmdphd/status/473119175997923328,http://twitter.com/mtmdphd
06/01/14,http://twitter.com/mtmdphd/status/473119354234896384,mtmdphd,Blanc #lymsm #ASCO14 - http://t.co/Vjn6YpcVBn,11.585546,http://twitter.com/mtmdphd/status/473119354234896384,http://twitter.com/mtmdphd
06/01/14,http://twitter.com/mtmdphd/status/473119683974270976,mtmdphd,"Blanc #lymsm #ASCO14 - SAR3419 - Background - TED 6828, TED 6829 http://t.co/nqisn9D6JH",10.006428,http://twitter.com/mtmdphd/status/473119683974270976,http://twitter.com/mtmdphd
06/01/14,http://twitter.com/mtmdphd/status/473119830334509056,mtmdphd,Blanc #lymsm #ASCO14 - SAR3419 - STARLYTE Study Objectives http://t.co/ji10hI30ks,10.24925,http://twitter.com/mtmdphd/status/473119830334509056,http://twitter.com/mtmdphd
06/01/14,http://twitter.com/mtmdphd/status/473119891458125824,mtmdphd,RT @VincentRK: Very impressive. MT “@mtmdphd: Forero-Torres #lymsm #ASCO14 - SGN-CD19A in rel/ref NHL (about 1/4 of PR still on Tx) http://…,9.743658,http://twitter.com/mtmdphd/status/473119891458125824,http://twitter.com/mtmdphd
06/01/14,http://twitter.com/mtmdphd/status/473120021091463169,mtmdphd,Blanc #lymsm #ASCO14 - SAR3419 - STARLYTE Study Design http://t.co/rL93m3jpKx,10.298223,http://twitter.com/mtmdphd/status/473120021091463169,http://twitter.com/mtmdphd
06/01/14,http://twitter.com/mtmdphd/status/473120189354348544,mtmdphd,Blanc #lymsm #ASCO14 - SAR3419 - Pt recruitment http://t.co/eVNV0hMbps,10.401555,http://twitter.com/mtmdphd/status/473120189354348544,http://twitter.com/mtmdphd
06/01/14,http://twitter.com/mtmdphd/status/473120314910846977,mtmdphd,Blanc #lymsm #ASCO14 - SAR3419 - Pt Characteristics (1) http://t.co/UQuVzu8BlY,10.338658,http://twitter.com/mtmdphd/status/473120314910846977,http://twitter.com/mtmdphd
06/01/14,http://twitter.com/mtmdphd/status/473120425120378880,mtmdphd,Blanc #lymsm #ASCO14 - SAR3419 - Disease Characteristics http://t.co/kcgegGLsR5,10.361639,http://twitter.com/mtmdphd/status/473120425120378880,http://twitter.com/mtmdphd
06/01/14,http://twitter.com/mtmdphd/status/473120567458291712,mtmdphd,Blanc #lymsm #ASCO14 - SAR3419 - STARLYTE Study status on May 2014 http://t.co/xBZ64Poj1g,10.159983,http://twitter.com/mtmdphd/status/473120567458291712,http://twitter.com/mtmdphd
06/01/14,http://twitter.com/mtmdphd/status/473120710601474048,mtmdphd,Blanc #lymsm #ASCO14 - SAR3419 - ORR 43.9% http://t.co/RCHfh6TvPH,11.0102415,http://twitter.com/mtmdphd/status/473120710601474048,http://twitter.com/mtmdphd
06/01/14,http://twitter.com/twittmanda/status/473120893497905152,twittmanda,RT @VincentRK: Very impressive. MT “@mtmdphd: Forero-Torres #lymsm #ASCO14 - SGN-CD19A in rel/ref NHL (about 1/4 of PR still on Tx) http://…,6.556737,http://twitter.com/twittmanda/status/473120893497905152,http://twitter.com/twittmanda
06/01/14,http://twitter.com/mtmdphd/status/473120925643456512,mtmdphd,Blanc #lymsm #ASCO14 - SAR3419 - Swimmer plot http://t.co/ql37GuBFFZ,10.404095,http://twitter.com/mtmdphd/status/473120925643456512,http://twitter.com/mtmdphd
06/01/14,http://twitter.com/mtmdphd/status/473121024234782720,mtmdphd,Blanc #lymsm #ASCO14 - SAR3419 - Overall Survival http://t.co/Z41ns6SX8u,10.399861,http://twitter.com/mtmdphd/status/473121024234782720,http://twitter.com/mtmdphd
06/01/14,http://twitter.com/mtmdphd/status/473121134721138689,mtmdphd,Blanc #lymsm #ASCO14 - SAR3419 - AEs http://t.co/V624aG2aJw,10.384487,http://twitter.com/mtmdphd/status/473121134721138689,http://twitter.com/mtmdphd
06/01/14,http://twitter.com/dmooneymd/status/473121292745723905,dmooneymd,"Trneny: cd19 adc, CoR, phase ii study in refr DLBCL. Orr 44%, achieved primary endpoint. Median DoR 5.5 mo. 38% g3/4 tox. #ASCO14 #lymsm",6.421643,http://twitter.com/dmooneymd/status/473121292745723905,http://twitter.com/dmooneymd
06/01/14,http://twitter.com/mtmdphd/status/473121370734620672,mtmdphd,Blanc #lymsm #ASCO14 - SAR3419 - Most frequent TEAEs http://t.co/qWCiwWlOxz,10.275645,http://twitter.com/mtmdphd/status/473121370734620672,http://twitter.com/mtmdphd
06/01/14,http://twitter.com/mtmdphd/status/473121609340182528,mtmdphd,Blanc #lymsm #ASCO14 - SAR3419 - CD19+ biomarker http://t.co/h3npZxEPpN,10.243094,http://twitter.com/mtmdphd/status/473121609340182528,http://twitter.com/mtmdphd
06/01/14,http://twitter.com/dmooneymd/status/473121721910689794,dmooneymd,Ocular toxicities with cd19 antibody drug conjugates seen to be class effect. Unclear reason. #lymsm #ASCO14,7.03874,http://twitter.com/dmooneymd/status/473121721910689794,http://twitter.com/dmooneymd
06/01/14,http://twitter.com/mtmdphd/status/473121796842332160,mtmdphd,Blanc #lymsm #ASCO14 - Biomarker analysis - STARLYTE http://t.co/Xz1RMvGSws,10.321279,http://twitter.com/mtmdphd/status/473121796842332160,http://twitter.com/mtmdphd
06/01/14,http://twitter.com/mtmdphd/status/473121933316620288,mtmdphd,Blanc #lymsm #ASCO14 - SAR3419 - Biomarker analysis by MYC/BCL2 expression http://t.co/hlTWKM4ucU,10.057855,http://twitter.com/mtmdphd/status/473121933316620288,http://twitter.com/mtmdphd
06/01/14,http://twitter.com/mtmdphd/status/473122226120953856,mtmdphd,"Blanc #lymsm #ASCO14 - SAR3419 - Conclusions - ORR 43.9%, favorable AE, biomarkers http://t.co/HgHUAAtEW5",10.639815,http://twitter.com/mtmdphd/status/473122226120953856,http://twitter.com/mtmdphd
06/01/14,http://twitter.com/mtmdphd/status/473122611757858816,mtmdphd,Federico #lymsm #ASCO14 - Ph2 Brentuximab ABVD in unTx HL - http://t.co/1PNpaHPqZ7,11.054013,http://twitter.com/mtmdphd/status/473122611757858816,http://twitter.com/mtmdphd
06/01/14,http://twitter.com/mtmdphd/status/473122821632425985,mtmdphd,Federico #lymsm #ASCO14 - Ph2 Brentuximab ABVD in unTx HL - Background http://t.co/4D5QNYwC0W,10.000404,http://twitter.com/mtmdphd/status/473122821632425985,http://twitter.com/mtmdphd
06/01/14,http://twitter.com/mtmdphd/status/473122902909657088,mtmdphd,Federico #lymsm #ASCO14 - Ph2 Brentuximab ABVD in unTx HL - CD30 target on HL RS cells w/ limited exp on nl cells,9.742271,http://twitter.com/mtmdphd/status/473122902909657088,http://twitter.com/mtmdphd
06/01/14,http://twitter.com/nxtstop1/status/473123038313979905,nxtstop1,Follow @mtmdphd: 4 detailed tweets re Forero-Torres #lymsm #ASCO14 - Ph1 SGN-CD19A in rel/ref NHL - interim analysis http://t.co/7OteZbYgJD”,6.5074186,http://twitter.com/nxtstop1/status/473123038313979905,http://twitter.com/nxtstop1
06/01/14,http://twitter.com/mtmdphd/status/473123100348121088,mtmdphd,Federico #lymsm #ASCO14 - Ph2 Brentuximab ABVD in unTx HL - 2c BV bvf standard chemo w/ ABVD +/- RT in Pts w/ limited/int stage HL,9.581761,http://twitter.com/mtmdphd/status/473123100348121088,http://twitter.com/mtmdphd
06/01/14,http://twitter.com/mtmdphd/status/473123308972826624,mtmdphd,Federico #lymsm #ASCO14 - Ph2 Brentuximab ABVD in unTx HL - Methods - Deauville Score (DS) included http://t.co/5uFTJ7MLCc,9.772772,http://twitter.com/mtmdphd/status/473123308972826624,http://twitter.com/mtmdphd
06/01/14,http://twitter.com/mtmdphd/status/473123424685289472,mtmdphd,Federico #lymsm #ASCO14 - Ph2 Brentuximab ABVD in unTx HL - Review methodology http://t.co/5kltoUKJ2z,9.955383,http://twitter.com/mtmdphd/status/473123424685289472,http://twitter.com/mtmdphd
06/01/14,http://twitter.com/benparsbenjamin/status/473123598409166848,benparsbenjamin,RT @mtmdphd: Federico #lymsm #ASCO14 - Ph2 Brentuximab ABVD in unTx HL - http://t.co/1PNpaHPqZ7,6.7684627,http://twitter.com/BenparsBenjamin/status/473123598409166848,http://twitter.com/benparsbenjamin
06/01/14,http://twitter.com/mtmdphd/status/473123735646765056,mtmdphd,Federico #lymsm #ASCO14 - Ph2 Brentuximab ABVD in unTx HL - Study Flow Chart http://t.co/folFQeMTD8,10.6572895,http://twitter.com/mtmdphd/status/473123735646765056,http://twitter.com/mtmdphd
06/01/14,http://twitter.com/henryjoncology/status/473123771776122880,henryjoncology,@doctorpemm thoughts on why ponatinib may not cause vascular occlusion in GIST #sarcoma? Why in CML #lymsm?,6.8148704,http://twitter.com/HenryJOncology/status/473123771776122880,http://twitter.com/henryjoncology
06/01/14,http://twitter.com/mtmdphd/status/473123842270191616,mtmdphd,Federico #lymsm #ASCO14 - Ph2 Brentuximab ABVD in unTx HL - Table 1 http://t.co/H7l7AKL8Ep,10.000404,http://twitter.com/mtmdphd/status/473123842270191616,http://twitter.com/mtmdphd
06/01/14,http://twitter.com/mtmdphd/status/473123968900427776,mtmdphd,Federico #lymsm #ASCO14 - Ph2 Brentuximab ABVD in unTx HL - Risk Strat by EORTC Criteria http://t.co/zD8ZQp8BHw,9.809769,http://twitter.com/mtmdphd/status/473123968900427776,http://twitter.com/mtmdphd
06/01/14,http://twitter.com/mtmdphd/status/473124223234621440,mtmdphd,Federico #lymsm #ASCO14 - Ph2 Brentuximab ABVD in unTx HL - Toxicity http://t.co/xvChWnJMYY,9.952639,http://twitter.com/mtmdphd/status/473124223234621440,http://twitter.com/mtmdphd
06/01/14,http://twitter.com/mtmdphd/status/473124371499089920,mtmdphd,Federico #lymsm #ASCO14 - Ph2 Brentuximab ABVD in unTx HL - PET - local vs. central http://t.co/hq5A9Oeax7,9.865899,http://twitter.com/mtmdphd/status/473124371499089920,http://twitter.com/mtmdphd
06/01/14,http://twitter.com/mtmdphd/status/473124412544532480,mtmdphd,Federico #lymsm #ASCO14 - Ph2 Brentuximab ABVD in unTx HL - Tx (n=12) http://t.co/PMCtN5FBK9,9.953028,http://twitter.com/mtmdphd/status/473124412544532480,http://twitter.com/mtmdphd
06/01/14,http://twitter.com/mtmdphd/status/473124549324992512,mtmdphd,Federico #lymsm #ASCO14 - Ph2 Brentuximab ABVD in unTx HL - PET Response by Risk Stratification http://t.co/ABCR9vEAQs,9.895092,http://twitter.com/mtmdphd/status/473124549324992512,http://twitter.com/mtmdphd
06/01/14,http://twitter.com/mtmdphd/status/473124692354945024,mtmdphd,Federico #lymsm #ASCO14 - Ph2 Brentuximab ABVD in unTx HL - Final Response http://t.co/uIngf72Iwm,11.219619,http://twitter.com/mtmdphd/status/473124692354945024,http://twitter.com/mtmdphd
06/01/14,http://twitter.com/mtmdphd/status/473124962229039104,mtmdphd,"Federico #lymsm #ASCO14 - Ph2 Brentuximab ABVD in unTx HL - 
Case 001 http://t.co/So3BrHEx0Z",10.030538,http://twitter.com/mtmdphd/status/473124962229039104,http://twitter.com/mtmdphd
06/01/14,http://twitter.com/mtmdphd/status/473125087999426561,mtmdphd,"Federico #lymsm #ASCO14 - Ph2 Brentuximab ABVD in unTx HL - Case 010, DS3 http://t.co/6YJNXLf4wP",9.930348,http://twitter.com/mtmdphd/status/473125087999426561,http://twitter.com/mtmdphd
06/01/14,http://twitter.com/mtmdphd/status/473125381017702400,mtmdphd,Federico #lymsm #ASCO14 - Ph2 Brentuximab ABVD in unTx HL - Conclusion - 2c BV well tolerated w/ 92% metabolic resp http://t.co/41ETO2VAJn,11.482506,http://twitter.com/mtmdphd/status/473125381017702400,http://twitter.com/mtmdphd
06/01/14,http://twitter.com/melmehdi/status/473125713496010753,melmehdi,RT @mtmdphd: Federico #lymsm #ASCO14 - Ph2 Brentuximab ABVD in unTx HL - Study Flow Chart http://t.co/folFQeMTD8,6.667024,http://twitter.com/melmehdi/status/473125713496010753,http://twitter.com/melmehdi
06/01/14,http://twitter.com/melmehdi/status/473125766994345984,melmehdi,RT @mtmdphd: Federico #lymsm #ASCO14 - Ph2 Brentuximab ABVD in unTx HL - Final Response http://t.co/uIngf72Iwm,6.681046,http://twitter.com/melmehdi/status/473125766994345984,http://twitter.com/melmehdi
06/01/14,http://twitter.com/mtmdphd/status/473125780550352896,mtmdphd,Janku #lymsm #ASCO14 - Younes background... http://t.co/sRd8mdFEKV,10.631612,http://twitter.com/mtmdphd/status/473125780550352896,http://twitter.com/mtmdphd
06/01/14,http://twitter.com/mtmdphd/status/473126148583723008,mtmdphd,"Janku #lymsm #ASCO14 mTORi (sirolimus) + HDACi (vorinostat) - Phase 1, 3+3 with MTD/RP2D exp cohorts http://t.co/qPkP3igmPe",9.759545,http://twitter.com/mtmdphd/status/473126148583723008,http://twitter.com/mtmdphd
06/01/14,http://twitter.com/mtmdphd/status/473126279861272576,mtmdphd,Janku #lymsm #ASCO14 mTORi (sirolimus) + HDACi (vorinostat) - schedule http://t.co/vfgGXwoKAu,10.041172,http://twitter.com/mtmdphd/status/473126279861272576,http://twitter.com/mtmdphd
06/01/14,http://twitter.com/benparsbenjamin/status/473126296634261504,benparsbenjamin,RT @mtmdphd: Federico #lymsm #ASCO14 - Ph2 Brentuximab ABVD in unTx HL - Conclusion - 2c BV well tolerated w/ 92% metabolic resp http://t.c…,6.3407407,http://twitter.com/BenparsBenjamin/status/473126296634261504,http://twitter.com/benparsbenjamin
06/01/14,http://twitter.com/melmehdi/status/473126441597804544,melmehdi,RT @mtmdphd: Federico #lymsm #ASCO14 - Ph2 Brentuximab ABVD in unTx HL - Conclusion - 2c BV well tolerated w/ 92% metabolic resp http://t.c…,6.3407407,http://twitter.com/melmehdi/status/473126441597804544,http://twitter.com/melmehdi
06/01/14,http://twitter.com/mtmdphd/status/473126476158877697,mtmdphd,Janku #lymsm #ASCO14 mTORi (sirolimus) + HDACi (vorinostat) - TCP DLT http://t.co/d29sP3fJPO,10.033077,http://twitter.com/mtmdphd/status/473126476158877697,http://twitter.com/mtmdphd
06/01/14,http://twitter.com/mtmdphd/status/473126644136558592,mtmdphd,Janku #lymsm #ASCO14 mTORi (sirolimus) + HDACi (vorinostat) - Pt characteristics (notes amended protocol) http://t.co/pFY57N1Bon,9.924024,http://twitter.com/mtmdphd/status/473126644136558592,http://twitter.com/mtmdphd
06/01/14,http://twitter.com/mtmdphd/status/473126855793725440,mtmdphd,Janku #lymsm #ASCO14 mTORi (sirolimus) + HDACi (vorinostat) - Waterfall plot (maximum reduction) http://t.co/4YpAHJa9YG,11.104019,http://twitter.com/mtmdphd/status/473126855793725440,http://twitter.com/mtmdphd
06/01/14,http://twitter.com/benparsbenjamin/status/473126926346113024,benparsbenjamin,RT @mtmdphd: Janku #lymsm #ASCO14 mTORi (sirolimus) + HDACi (vorinostat) - Waterfall plot (maximum reduction) http://t.co/4YpAHJa9YG,6.686274,http://twitter.com/BenparsBenjamin/status/473126926346113024,http://twitter.com/benparsbenjamin
06/01/14,http://twitter.com/mtmdphd/status/473127014069972993,mtmdphd,Janku #lymsm #ASCO14 mTORi (sirolimus) + HDACi (vorinostat) - Efficacy Summary http://t.co/dvRYRnxph1,10.675323,http://twitter.com/mtmdphd/status/473127014069972993,http://twitter.com/mtmdphd
06/01/14,http://twitter.com/dmooneymd/status/473127073054076928,dmooneymd,"Phase I study of vorinostat and sirolimus in refractory Hodgkin dz. Orr 57%, median fu 5.4 mos with median ttf not reached. #lymsm #ASCO14",6.681776,http://twitter.com/dmooneymd/status/473127073054076928,http://twitter.com/dmooneymd
06/01/14,http://twitter.com/mtmdphd/status/473127215694364672,mtmdphd,Janku #lymsm #ASCO14 mTORi (sirolimus) + HDACi (vorinostat) - Toxicity http://t.co/99iCVzsXob,10.057855,http://twitter.com/mtmdphd/status/473127215694364672,http://twitter.com/mtmdphd
06/01/14,http://twitter.com/melmehdi/status/473127223760011264,melmehdi,RT @mtmdphd: Janku #lymsm #ASCO14 mTORi (sirolimus) + HDACi (vorinostat) - Efficacy Summary http://t.co/dvRYRnxph1,6.681046,http://twitter.com/melmehdi/status/473127223760011264,http://twitter.com/melmehdi
06/01/14,http://twitter.com/mtmdphd/status/473127584151400448,mtmdphd,"Janku #lymsm #ASCO14 mTORi (sirolimus) + HDACi (vorinostat) - Case refractory to 9 prior Rx including Auto, Allo, BV http://t.co/JhcxbvVBGs",10.583143,http://twitter.com/mtmdphd/status/473127584151400448,http://twitter.com/mtmdphd
06/01/14,http://twitter.com/melmehdi/status/473127771418685440,melmehdi,"RT @mtmdphd: Janku #lymsm #ASCO14 mTORi (sirolimus) + HDACi (vorinostat) - Case refractory to 9 prior Rx including Auto, Allo, BV http://t.…",6.6124372,http://twitter.com/melmehdi/status/473127771418685440,http://twitter.com/melmehdi
06/01/14,http://twitter.com/mtmdphd/status/473128010057809920,mtmdphd,Janku #lymsm #ASCO14 mTORi (sirolimus) + HDACi (vorinostat) - Case http://t.co/jkO6G1N3Qd,10.038819,http://twitter.com/mtmdphd/status/473128010057809920,http://twitter.com/mtmdphd
06/01/14,http://twitter.com/mtmdphd/status/473128210675564544,mtmdphd,Janku #lymsm #ASCO14 mTORi (sirolimus) + HDACi (vorinostat) - Conclusions - new alternative mTORi + HDACi considered http://t.co/IbcBYjS45b,9.669017,http://twitter.com/mtmdphd/status/473128210675564544,http://twitter.com/mtmdphd
06/01/14,http://twitter.com/mtmdphd/status/473128412027289600,mtmdphd,Janku #lymsm #ASCO14 mTORi (sirolimus) + HDACi (vorinostat) - Shout out to @DrAnasYounes and @LymphomaMyeloma Dept http://t.co/G3T1TBcWur,9.860833,http://twitter.com/mtmdphd/status/473128412027289600,http://twitter.com/mtmdphd
06/01/14,http://twitter.com/mtmdphd/status/473128943068123136,mtmdphd,. @DrAnasYounes of @MSKCC_OncoNotes #lymsm #ASCO14 - Tx in Early Stage HL http://t.co/9cUgxe6lR8,10.435552,http://twitter.com/mtmdphd/status/473128943068123136,http://twitter.com/mtmdphd
06/01/14,http://twitter.com/mtmdphd/status/473129436293128193,mtmdphd,". @DrAnasYounes #lymsm #ASCO14 - HD13 Early-stage favorable HL (now use 20 Gy IF-RT), elim arms 2 &amp; 4 http://t.co/uYjj1rna4Z",9.836594,http://twitter.com/mtmdphd/status/473129436293128193,http://twitter.com/mtmdphd
06/01/14,http://twitter.com/mtmdphd/status/473129876959285248,mtmdphd,. @DrAnasYounes #lymsm #ASCO14 - PFS in randomized Pet -ve population -&gt; at one point elim XRT and chemo http://t.co/49Ol4Nnmnm,10.204943,http://twitter.com/mtmdphd/status/473129876959285248,http://twitter.com/mtmdphd
06/01/14,http://twitter.com/drcbsteer/status/473130069649817601,drcbsteer,RT @mtmdphd: Janku #lymsm #ASCO14 mTORi (sirolimus) + HDACi (vorinostat) - Waterfall plot (maximum reduction) http://t.co/4YpAHJa9YG,6.686274,http://twitter.com/drcbsteer/status/473130069649817601,http://twitter.com/drcbsteer
06/01/14,http://twitter.com/mtmdphd/status/473130177653125120,mtmdphd,. @DrAnasYounes #lymsm #ASCO14 - MSKCC 11-142 - Results for first 33 evaluable Pts http://t.co/Zl8uCxP2IX,9.987178,http://twitter.com/mtmdphd/status/473130177653125120,http://twitter.com/mtmdphd
06/01/14,http://twitter.com/mtmdphd/status/473130643518652416,mtmdphd,. @DrAnasYounes #lymsm #ASCO14 - Relapse after ASCT - OS by Era of Transplant #bmtsm http://t.co/HYU6QzXBcN,11.211212,http://twitter.com/mtmdphd/status/473130643518652416,http://twitter.com/mtmdphd
06/01/14,http://twitter.com/mtmdphd/status/473130826813952000,mtmdphd,. @DrAnasYounes #lymsm #ASCO14 - Single agent activity of new agents in post SCT relapsed cHL http://t.co/UlxWE0vGlJ,10.321634,http://twitter.com/mtmdphd/status/473130826813952000,http://twitter.com/mtmdphd
06/01/14,http://twitter.com/dmooneymd/status/473130851400572930,dmooneymd,Younes: can we eliminate chemotherapy in frontline setting from Hodgkin disease in lieu of Brentuximab? #lymsm #ASCO14,6.9897313,http://twitter.com/dmooneymd/status/473130851400572930,http://twitter.com/dmooneymd
06/01/14,http://twitter.com/mtmdphd/status/473131079629828097,mtmdphd,. @DrAnasYounes #lymsm #ASCO14 - Mocetinostat in rel HL - Waterfall plot of clinical responses http://t.co/7S2Tg7VCmj,10.105692,http://twitter.com/mtmdphd/status/473131079629828097,http://twitter.com/mtmdphd
06/01/14,http://twitter.com/mtmdphd/status/473131247448129537,mtmdphd,. @DrAnasYounes #lymsm #ASCO14 - Activity of PI3K/mTOR inhibitors in lymphoma http://t.co/b8FAQN7NiA,11.47792,http://twitter.com/mtmdphd/status/473131247448129537,http://twitter.com/mtmdphd
06/01/14,http://twitter.com/mtmdphd/status/473131687090876417,mtmdphd,". @DrAnasYounes #lymsm #ASCO14 - HL Conclusions &amp; Future Directions - BV at center - HDACi, PD1, PI3K/mTORi, chemo http://t.co/dgAweXzNwJ",10.349555,http://twitter.com/mtmdphd/status/473131687090876417,http://twitter.com/mtmdphd
06/01/14,http://twitter.com/mtmdphd/status/473132138112757760,mtmdphd,I agree MT @JSweetenhamMD: Anas Younes is doing a great job reviewing HL therapy at #ASCO14 #lymsm,10.496978,http://twitter.com/mtmdphd/status/473132138112757760,http://twitter.com/mtmdphd
06/01/14,http://twitter.com/dsobek/status/473132817963319296,dsobek,RT @mtmdphd: Federico #lymsm #ASCO14 - Ph2 Brentuximab ABVD in unTx HL - Final Response http://t.co/uIngf72Iwm,9.875315,http://twitter.com/dsobek/status/473132817963319296,http://twitter.com/dsobek
06/01/14,http://twitter.com/gmailhalcon/status/473133493799895040,gmailhalcon,"RT @mtmdphd: . @DrAnasYounes #lymsm #ASCO14 - HL Conclusions &amp; Future Directions - BV at center - HDACi, PD1, PI3K/mTORi, chemo http://t.co…",6.381523,http://twitter.com/GmailHalcon/status/473133493799895040,http://twitter.com/gmailhalcon
06/01/14,http://twitter.com/mnewtonpharmd/status/473139353514827776,mnewtonpharmd,RT @mtmdphd: Federico #lymsm #ASCO14 - Ph2 Brentuximab ABVD in unTx HL - Conclusion - 2c BV well tolerated w/ 92% metabolic resp http://t.c…,6.3407407,http://twitter.com/mnewtonPharmD/status/473139353514827776,http://twitter.com/mnewtonpharmd
06/01/14,http://twitter.com/drmiguelperales/status/473153243980124160,drmiguelperales,"RT @mtmdphd: Blanc #lymsm #ASCO14 - SAR3419 - Conclusions - ORR 43.9%, favorable AE, biomarkers http://t.co/HgHUAAtEW5",6.641192,http://twitter.com/DrMiguelPerales/status/473153243980124160,http://twitter.com/drmiguelperales
06/01/14,http://twitter.com/transplant_doc/status/473170688681840640,transplant_doc,RT @mtmdphd: . @DrAnasYounes #lymsm #ASCO14 - Relapse after ASCT - OS by Era of Transplant #bmtsm http://t.co/HYU6QzXBcN,6.754908,http://twitter.com/Transplant_Doc/status/473170688681840640,http://twitter.com/transplant_doc
06/01/14,http://twitter.com/asco/status/473173456088231938,asco,At the Lymphoma/Plasma Cell Disorders track at #ASCO14? Catch up on recent research via #ASCOConnection http://t.co/aGG0ROjxJF #lymsm,11.154681,http://twitter.com/ASCO/status/473173456088231938,http://twitter.com/asco
06/01/14,http://twitter.com/cancer_genetics/status/473175300948647936,cancer_genetics,RT @ASCO: At the Lymphoma/Plasma Cell Disorders track at #ASCO14? Catch up on recent research via #ASCOConnection http://t.co/aGG0ROjxJF #l…,7.024276,http://twitter.com/Cancer_Genetics/status/473175300948647936,http://twitter.com/cancer_genetics
06/01/14,http://twitter.com/drmiguelperales/status/473181877160124418,drmiguelperales,RT @mtmdphd: Federico #lymsm #ASCO14 - Ph2 Brentuximab ABVD in unTx HL - Conclusion - 2c BV well tolerated w/ 92% metabolic resp http://t.c…,6.3407407,http://twitter.com/DrMiguelPerales/status/473181877160124418,http://twitter.com/drmiguelperales
06/01/14,http://twitter.com/gmcrotty/status/473192939456561154,gmcrotty,RT @mtmdphd: Federico #lymsm #ASCO14 - Ph2 Brentuximab ABVD in unTx HL - Conclusion - 2c BV well tolerated w/ 92% metabolic resp http://t.c…,6.3407407,http://twitter.com/gmcrotty/status/473192939456561154,http://twitter.com/gmcrotty
06/01/14,http://twitter.com/drmiguelperales/status/473201363921301504,drmiguelperales,RT @mtmdphd: . @DrAnasYounes #lymsm #ASCO14 - Activity of PI3K/mTOR inhibitors in lymphoma http://t.co/b8FAQN7NiA,7.0578666,http://twitter.com/DrMiguelPerales/status/473201363921301504,http://twitter.com/drmiguelperales
06/01/14,http://twitter.com/drmiguelperales/status/473202046577803265,drmiguelperales,MT @mtmdphd  .@DrAnasYounes #lymsm #ASCO14 - MSKCC 11-142 @sloan_kettering - Results for first 33 evaluable Pts http://t.co/pRN50STy9I,6.650315,http://twitter.com/DrMiguelPerales/status/473202046577803265,http://twitter.com/drmiguelperales
06/01/14,http://twitter.com/aricaroline/status/473202959686197248,aricaroline,RT @mtmdphd: . @DrAnasYounes #lymsm #ASCO14 - Activity of PI3K/mTOR inhibitors in lymphoma http://t.co/b8FAQN7NiA,7.0578666,http://twitter.com/aricaroline/status/473202959686197248,http://twitter.com/aricaroline
06/02/14,http://twitter.com/benparsbenjamin/status/473333646179725312,benparsbenjamin,RT @mtmdphd: . @DrAnasYounes #lymsm #ASCO14 - Relapse after ASCT - OS by Era of Transplant #bmtsm http://t.co/HYU6QzXBcN,6.754908,http://twitter.com/BenparsBenjamin/status/473333646179725312,http://twitter.com/benparsbenjamin
06/02/14,http://twitter.com/maurerstats/status/473456621989797888,maurerstats,Lenalidomide Plus R-CHOP in DLBCL | #ASCO14 Daily News summary @GregNowakowski @MayoClinicLymph http://t.co/QHlBqcuD0T #lymsm,6.848228,http://twitter.com/MaurerStats/status/473456621989797888,http://twitter.com/maurerstats
06/02/14,http://twitter.com/drmarkham/status/473472860624003072,drmarkham,Cardiovascular disease persists in Hodgkin lymphoma survivors at least 35 years out from treatment. http://t.co/vghtyysqhP #ASCO14 #lymsm,13.155962,http://twitter.com/DrMarkham/status/473472860624003072,http://twitter.com/drmarkham
06/02/14,http://twitter.com/maurerstats/status/473473514360414208,maurerstats,MT @DrMarkham Cardiovascular disease persists in Hodgkin #lymphoma survivors &gt;35 yrs out from trtmnt. http://t.co/cXmKqvgRXq  #ASCO14 #lymsm,6.956241,http://twitter.com/MaurerStats/status/473473514360414208,http://twitter.com/maurerstats
06/02/14,http://twitter.com/drattai/status/473473525643505664,drattai,RT @DrMarkham: Cardiovascular disease persists in Hodgkin lymphoma survivors at least 35 years out from treatment. http://t.co/vghtyysqhP #…,10.301745,http://twitter.com/DrAttai/status/473473525643505664,http://twitter.com/drattai
06/02/14,http://twitter.com/asco/status/473474443466248192,asco,RT @DrMarkham: Cardiovascular disease persists in Hodgkin lymphoma survivors at least 35 years out from treatment. http://t.co/vghtyysqhP #…,10.390083,http://twitter.com/ASCO/status/473474443466248192,http://twitter.com/asco
06/02/14,http://twitter.com/emperatrizrios/status/473475808502489088,emperatrizrios,RT @DrMarkham: Cardiovascular disease persists in Hodgkin lymphoma survivors at least 35 years out from treatment. http://t.co/vghtyysqhP #…,7.051415,http://twitter.com/EmperatrizRios/status/473475808502489088,http://twitter.com/emperatrizrios
06/02/14,http://twitter.com/bmtjolene/status/473476311155867649,bmtjolene,RT @DrMarkham: Cardiovascular disease persists in Hodgkin lymphoma survivors at least 35 years out from treatment. http://t.co/vghtyysqhP #…,7.051415,http://twitter.com/BMTJolene/status/473476311155867649,http://twitter.com/bmtjolene
06/02/14,http://twitter.com/pallioncmd423/status/473476497072984066,pallioncmd423,RT @DrMarkham: Cardiovascular disease persists in Hodgkin lymphoma survivors at least 35 years out from treatment. http://t.co/vghtyysqhP #…,7.051415,http://twitter.com/pallioncmd423/status/473476497072984066,http://twitter.com/pallioncmd423
06/02/14,http://twitter.com/wordbistro/status/473476637242449921,wordbistro,RT @DrMarkham: Cardiovascular disease persists in Hodgkin lymphoma survivors at least 35 years out from treatment. http://t.co/vghtyysqhP #…,7.051415,http://twitter.com/wordbistro/status/473476637242449921,http://twitter.com/wordbistro
06/02/14,http://twitter.com/drmarkham/status/473485710465716224,drmarkham,RT @ASCO: R2CHOP may overcome negative prognosis of non-GBC phenotype in DLBCL http://t.co/eOpWAqjMVG #ASCO14 #lymsm,10.045843,http://twitter.com/DrMarkham/status/473485710465716224,http://twitter.com/drmarkham
06/02/14,http://twitter.com/emanduhaiby/status/473487859580956672,emanduhaiby,RT @DrMarkham: Cardiovascular disease persists in Hodgkin lymphoma survivors at least 35 years out from treatment. http://t.co/vghtyysqhP #…,7.051415,http://twitter.com/EmanDuhaiby/status/473487859580956672,http://twitter.com/emanduhaiby
06/02/14,http://twitter.com/lesleylesleys/status/473499928791363584,lesleylesleys,RT @DrMarkham: Cardiovascular disease persists in Hodgkin lymphoma survivors at least 35 years out from treatment. http://t.co/vghtyysqhP #…,7.051415,http://twitter.com/LesleyLesleys/status/473499928791363584,http://twitter.com/lesleylesleys
06/02/14,http://twitter.com/drcbsteer/status/473507119506145280,drcbsteer,RT @DrMarkham: Cardiovascular disease persists in Hodgkin lymphoma survivors at least 35 years out from treatment. http://t.co/vghtyysqhP #…,7.051415,http://twitter.com/drcbsteer/status/473507119506145280,http://twitter.com/drcbsteer
06/02/14,http://twitter.com/maurerstats/status/473508610673098752,maurerstats,MT @ASCO At Lymphoma/Plasma Cell Disorders #ASCO14 track? Recent EFS24 in DLBCL research via #ASCOConnection http://t.co/JuOU8yVEoV #lymsm,6.7684627,http://twitter.com/MaurerStats/status/473508610673098752,http://twitter.com/maurerstats
06/02/14,http://twitter.com/mtmdphd/status/473519439829544960,mtmdphd,Lymphoma and plasma cell disorder posters - 6/2 1:15-5:00 p #lymsm #mmsm #ASCO14 http://t.co/hT1u7chOd2,10.213995,http://twitter.com/mtmdphd/status/473519439829544960,http://twitter.com/mtmdphd
06/02/14,http://twitter.com/drmarkham/status/473557057422233601,drmarkham,"Now attending: Lymphoma education session, focusing on mantle cell lymphoma first. http://t.co/NZ7Z4hXlbQ #asco14 #lymsm",10.5905695,http://twitter.com/DrMarkham/status/473557057422233601,http://twitter.com/drmarkham
06/02/14,http://twitter.com/drmarkham/status/473558008598122496,drmarkham,Dr. M.H. Dreyling: Characterization of indolent forms of mantle cell lymphoma requires further studies. #ASCO14 #lymsm,10.307961,http://twitter.com/DrMarkham/status/473558008598122496,http://twitter.com/drmarkham
06/02/14,http://twitter.com/drmarkham/status/473558260109553666,drmarkham,Dreyling: Minimal residual disease in MCL is a powerful predictor but its use should be limited to clinical trials. #ASCO14 #lymsm,10.3139305,http://twitter.com/DrMarkham/status/473558260109553666,http://twitter.com/drmarkham
06/02/14,http://twitter.com/drmiguelperales/status/473565063962689537,drmiguelperales,RT @DrMarkham: Cardiovascular disease persists in Hodgkin lymphoma survivors at least 35 years out from treatment. http://t.co/vghtyysqhP #…,7.051415,http://twitter.com/DrMiguelPerales/status/473565063962689537,http://twitter.com/drmiguelperales
06/02/14,http://twitter.com/robinwarshaw/status/473569437791322112,robinwarshaw,RT @DrMarkham: Cardiovascular disease persists in Hodgkin lymphoma survivors at least 35 years out from treatment. http://t.co/vghtyysqhP #…,7.051415,http://twitter.com/robinwarshaw/status/473569437791322112,http://twitter.com/robinwarshaw
06/03/14,http://twitter.com/mtmdphd/status/473872611248992257,mtmdphd,“@drsam: CD137 + ritux in NHL combo planned #ASCO14”.  #lymsm,11.181889,http://twitter.com/mtmdphd/status/473872611248992257,http://twitter.com/mtmdphd
06/03/14,http://twitter.com/drcbsteer/status/473879008745373696,drcbsteer,RT @mtmdphd: “@drsam: CD137 + ritux in NHL combo planned #ASCO14”.  #lymsm,7.1275167,http://twitter.com/drcbsteer/status/473879008745373696,http://twitter.com/drcbsteer
06/03/14,http://twitter.com/asbmt/status/473915099712094208,asbmt,June eNews now available: http://t.co/bYERGqd5vj Read the msg from our President @sgiraltbmtdoc #bmtsm #lymsm #chemotherapy #GVHD #ASBMTCCF,9.094255,http://twitter.com/ASBMT/status/473915099712094208,http://twitter.com/asbmt
06/03/14,http://twitter.com/maurerstats/status/473917052407644161,maurerstats,MT @chadinabhan Bevacizumab does not improve outcomes of DLBCL patients treated with R-CHOP http://t.co/3ofS0ZCZdF …#lymsm,7.961148,http://twitter.com/MaurerStats/status/473917052407644161,http://twitter.com/maurerstats
06/03/14,http://twitter.com/sgiraltbmtdoc/status/473938709373399041,sgiraltbmtdoc,RT @ASBMT: June eNews now available: http://t.co/bYERGqd5vj Read the msg from our President @sgiraltbmtdoc #bmtsm #lymsm #chemotherapy #GVH…,6.799868,http://twitter.com/sgiraltbmtdoc/status/473938709373399041,http://twitter.com/sgiraltbmtdoc
06/03/14,http://twitter.com/maurerstats/status/473941389932101632,maurerstats,ALK- ALCL is genetically heterogeneous disease w/ disparate clinical outcomes. Blood 1st ed @ASH_hematology http://t.co/eBx2xprwyf  #lymsm,7.016289,http://twitter.com/MaurerStats/status/473941389932101632,http://twitter.com/maurerstats
06/03/14,http://twitter.com/mtmdphd/status/473963033228632067,mtmdphd,"MT @timfenske: Phase 2 trial of GS-9973, a selective Syk inhibitor, in R/R CLL. ORR 64%    http://t.co/RV7hRbety1 #ASCO14 #lymsm",9.966168,http://twitter.com/mtmdphd/status/473963033228632067,http://twitter.com/mtmdphd
06/04/14,http://twitter.com/mtmdphd/status/474141580538818561,mtmdphd,MT @DrDavidStraus: Age but not G-CSF use increases risk of bleomycin-induced lung toxicity. #ASCO14 Abstract http://t.co/okZjyx70sG #lymsm,9.922362,http://twitter.com/mtmdphd/status/474141580538818561,http://twitter.com/mtmdphd
06/04/14,http://twitter.com/maurerstats/status/474182870911574016,maurerstats,ALK neg ALCL is genetically heterogeneous w/ disparate clinical outcomes. Blood 1st ed @ASH_hematology http://t.co/eBx2xprwyf … #lymsm,7.1838408,http://twitter.com/MaurerStats/status/474182870911574016,http://twitter.com/maurerstats
06/04/14,http://twitter.com/mdandersonnews/status/474184477380329473,mdandersonnews,A #lymphoma survivor shares her #cancer journey: http://t.co/Sep6NkmgLj #cancersurvivor #lymsm #endcancer http://t.co/TwRjD2Gksj,12.790334,http://twitter.com/MDAndersonNews/status/474184477380329473,http://twitter.com/mdandersonnews
06/04/14,http://twitter.com/lauriemacdon/status/474185212629622784,lauriemacdon,RT @MDAndersonNews: A #lymphoma survivor shares her #cancer journey: http://t.co/Sep6NkmgLj #cancersurvivor #lymsm #endcancer http://t.co/T…,7.412684,http://twitter.com/lauriemacdon/status/474185212629622784,http://twitter.com/lauriemacdon
06/04/14,http://twitter.com/veconilla/status/474185442011938816,veconilla,RT @MDAndersonNews: A #lymphoma survivor shares her #cancer journey: http://t.co/Sep6NkmgLj #cancersurvivor #lymsm #endcancer http://t.co/T…,7.412684,http://twitter.com/Veconilla/status/474185442011938816,http://twitter.com/veconilla
06/04/14,http://twitter.com/saludhealthinfo/status/474186104913268736,saludhealthinfo,RT @MDAndersonNews: A #lymphoma survivor shares her #cancer journey: http://t.co/Sep6NkmgLj #cancersurvivor #lymsm #endcancer http://t.co/T…,10.725674,http://twitter.com/SaludHEALTHinfo/status/474186104913268736,http://twitter.com/saludhealthinfo
06/04/14,http://twitter.com/drmiguelperales/status/474191943346700288,drmiguelperales,Stem Cell Transplant Clinical trials @sloan_kettering http://t.co/9gme4uYCxQ  http://t.co/UO5s7X5lkw  #bmtsm #mmsm #leusm #lymsm,8.718429,http://twitter.com/DrMiguelPerales/status/474191943346700288,http://twitter.com/drmiguelperales
06/04/14,http://twitter.com/drmiguelperales/status/474192410919309313,drmiguelperales,Open trial @sloan_kettering AutoSCT + CD19-CAR TCells for Rel/Ref B-NHL #lymphoma http://t.co/AQwirS9pnq    #bmtsm #lymsm,7.5882726,http://twitter.com/DrMiguelPerales/status/474192410919309313,http://twitter.com/drmiguelperales
06/04/14,http://twitter.com/dioncapital/status/474192568428019712,dioncapital,RT @DrMiguelPerales: Open trial @sloan_kettering AutoSCT + CD19-CAR TCells for Rel/Ref B-NHL #lymphoma http://t.co/AQwirS9pnq    #bmtsm #ly…,6.590678,http://twitter.com/DionCapital/status/474192568428019712,http://twitter.com/dioncapital
06/04/14,http://twitter.com/mtmdphd/status/474193260270059520,mtmdphd,MT @StefanoLuminari: #ASCO14 @GregNowakowski conclusion slide on R2CHOP for DLBCL @lymphomahub http://t.co/twAyy7QE5V #EAOnc #lymsm,11.106658,http://twitter.com/mtmdphd/status/474193260270059520,http://twitter.com/mtmdphd
06/04/14,http://twitter.com/eaonc/status/474193446971113472,eaonc,MT @StefanoLuminari: #ASCO14 @GregNowakowski conclusion slide on R2CHOP for DLBCL @lymphomahub http://t.co/oGrF3mLbxu #EAOnc #lymsm,8.278937,http://twitter.com/eaonc/status/474193446971113472,http://twitter.com/eaonc
06/04/14,http://twitter.com/mtmdphd/status/474193886240587776,mtmdphd,MT @StefanoLuminari: #ASCO14 O'connors summary slide about exportins - XPO-1/CRM-1 @lymphomahub http://t.co/0lLDF1V6J8 #lymsm,10.441495,http://twitter.com/mtmdphd/status/474193886240587776,http://twitter.com/mtmdphd
06/04/14,http://twitter.com/maverickny/status/474194561204752384,maverickny,RT @DrMiguelPerales: Open trial @sloan_kettering AutoSCT + CD19-CAR TCells for Rel/Ref B-NHL #lymphoma http://t.co/sTdT1ngii0 #bmtsm #lymsm,10.039867,http://twitter.com/MaverickNY/status/474194561204752384,http://twitter.com/maverickny
06/04/14,http://twitter.com/drmiguelperales/status/474195093696806913,drmiguelperales,RT @mtmdphd: MT @StefanoLuminari: #ASCO14 @GregNowakowski conclusion slide on R2CHOP for DLBCL @lymphomahub http://t.co/twAyy7QE5V #EAOnc #…,6.7046185,http://twitter.com/DrMiguelPerales/status/474195093696806913,http://twitter.com/drmiguelperales
06/04/14,http://twitter.com/drmiguelperales/status/474195431908724736,drmiguelperales,Open trial @sloan_kettering Allo-SCT for patient with advanced #Hodgkin lymphoma http://t.co/HdENXjqXNe  #lymsm #bmtsm,7.066965,http://twitter.com/DrMiguelPerales/status/474195431908724736,http://twitter.com/drmiguelperales
06/04/14,http://twitter.com/drmiguelperales/status/474195490368913408,drmiguelperales,Open trial @sloan_kettering Ph 2 Study AutoSCT w maintenance Romidepsin in T cell NHL. #lymphoma http://t.co/fdp04puRk7  #lymsm #bmtsm,6.9971137,http://twitter.com/DrMiguelPerales/status/474195490368913408,http://twitter.com/drmiguelperales
06/04/14,http://twitter.com/natedahlpharmd/status/474198410757558272,natedahlpharmd,RT @DrMiguelPerales: Stem Cell Transplant Clinical trials @sloan_kettering http://t.co/9gme4uYCxQ  http://t.co/UO5s7X5lkw  #bmtsm #mmsm #le…,6.991569,http://twitter.com/NateDahlPharmD/status/474198410757558272,http://twitter.com/natedahlpharmd
06/04/14,http://twitter.com/enfermeria_cceo/status/474204973631541248,enfermeria_cceo,RT @MDAndersonNews: A #lymphoma survivor shares her #cancer journey: http://t.co/Sep6NkmgLj #cancersurvivor #lymsm #endcancer http://t.co/T…,7.412684,http://twitter.com/enfermeria_cceo/status/474204973631541248,http://twitter.com/enfermeria_cceo
06/04/14,http://twitter.com/fashionhitlist/status/474209476652724224,fashionhitlist,RT @MDAndersonNews: A #lymphoma survivor shares her #cancer journey: http://t.co/Sep6NkmgLj #cancersurvivor #lymsm #endcancer http://t.co/T…,7.412684,http://twitter.com/FashionHitList/status/474209476652724224,http://twitter.com/fashionhitlist
06/04/14,http://twitter.com/mtmdphd/status/474263129443282944,mtmdphd,#EAOnc E1A10 - Phase I/II Study of VRd + Temsirolimus in Waldenstrom's Macroglobulinemia  http://t.co/Ls2UjWJX8n #mmsm #lymsm,9.831666,http://twitter.com/mtmdphd/status/474263129443282944,http://twitter.com/mtmdphd
06/04/14,http://twitter.com/mayocliniclymph/status/474266548509491201,mayocliniclymph,"#Lymphomathon THIS Sat. June 7, in Minneapolis, MN! Join Mayo Clinic team; support, honor #lymphoma patients. #lymsm http://t.co/N0kccqwENo",7.275571,http://twitter.com/MayoClinicLymph/status/474266548509491201,http://twitter.com/mayocliniclymph
06/05/14,http://twitter.com/lymphomahub/status/474538578044026880,lymphomahub,RT @mtmdphd: MT @StefanoLuminari: #ASCO14 O'connors summary slide about exportins - XPO-1/CRM-1 @lymphomahub http://t.co/0lLDF1V6J8 #lymsm,6.4508076,http://twitter.com/lymphomahub/status/474538578044026880,http://twitter.com/lymphomahub
06/05/14,http://twitter.com/lymphomahub/status/474538621803175937,lymphomahub,RT @mtmdphd: MT @StefanoLuminari: #ASCO14 @GregNowakowski conclusion slide on R2CHOP for DLBCL @lymphomahub http://t.co/twAyy7QE5V #EAOnc #…,6.7046185,http://twitter.com/lymphomahub/status/474538621803175937,http://twitter.com/lymphomahub
06/05/14,http://twitter.com/maurerstats/status/474546403562491904,maurerstats,"MT @Lymphoma_Doc Nice DLBCL review by Dr. Witzig  - time to use biology/knowledge to treat @MayoClinicLymph 
http://t.co/Xjz7iEeLP5 #lymsm",7.0578666,http://twitter.com/MaurerStats/status/474546403562491904,http://twitter.com/maurerstats
06/05/14,http://twitter.com/maurerstats/status/474562494233473025,maurerstats,MT @lymphomahub Worth signing up for: lenalidomide+R2CHOP in DLBCL presented by @GregNowakowski at #ASCO2014 http://t.co/iCXq72wFmK #lymsm,7.837447,http://twitter.com/MaurerStats/status/474562494233473025,http://twitter.com/maurerstats
06/05/14,http://twitter.com/lymphomahub/status/474593698001727489,lymphomahub,RT @eaonc: MT @StefanoLuminari: #ASCO14 @GregNowakowski conclusion slide on R2CHOP for DLBCL @lymphomahub http://t.co/oGrF3mLbxu #EAOnc #ly…,6.5897107,http://twitter.com/lymphomahub/status/474593698001727489,http://twitter.com/lymphomahub
06/05/14,http://twitter.com/mtmdphd/status/474623194562043904,mtmdphd,Socioeconomic disparities in mortality after DLBCL in modern treatment era - Tao et al. Blood http://t.co/vF7sOSiS16 #lymsm,11.0137415,http://twitter.com/mtmdphd/status/474623194562043904,http://twitter.com/mtmdphd
06/05/14,http://twitter.com/woodbd/status/474630761099038720,woodbd,RT @mtmdphd: Socioeconomic disparities in mortality after DLBCL in modern treatment era - Tao et al. Blood http://t.co/vF7sOSiS16 #lymsm,7.011854,http://twitter.com/WoodBD/status/474630761099038720,http://twitter.com/woodbd
06/06/14,http://twitter.com/lymphomahub/status/474829438669316096,lymphomahub,RT @MaurerStats: MT @lymphomahub Worth signing up for: lenalidomide+R2CHOP in DLBCL presented by @GregNowakowski at #ASCO2014 http://t.co/i…,6.770124,http://twitter.com/lymphomahub/status/474829438669316096,http://twitter.com/lymphomahub
06/06/14,http://twitter.com/drmiguelperales/status/474981165334798336,drmiguelperales,#cordbloodsymp14 similar outcomes for lymphoma using different graft sources for alloHCT @CIBMTR study #lymsm #bmtsm http://t.co/hgB5wJV90L,7.023064,http://twitter.com/DrMiguelPerales/status/474981165334798336,http://twitter.com/drmiguelperales
06/07/14,http://twitter.com/mayocliniclymph/status/475324051942940672,mayocliniclymph,"#Research #video: Vitamin D in patients w/ #lymphoma (#DLBCL) strongly assoc. w/ cancer progression, survival. http://t.co/UGNpoAFjR0 #lymsm",8.612564,http://twitter.com/MayoClinicLymph/status/475324051942940672,http://twitter.com/mayocliniclymph
06/07/14,http://twitter.com/maurerstats/status/475328690201436161,maurerstats,"RT @MayoClinicLymph: #Research #video: Vitamin D in patients w/ #lymphoma (#DLBCL) strongly assoc. w/ cancer progression, survival. http://…",7.111302,http://twitter.com/MaurerStats/status/475328690201436161,http://twitter.com/maurerstats
06/10/14,http://twitter.com/chemoadvisor/status/476314117180227584,chemoadvisor,Mogamulizumab: An Option for Relapsed T-cell Lymphomas? #lymphoma #lymsm http://t.co/YxYQMDtxLL,7.0543427,http://twitter.com/ChemoAdvisor/status/476314117180227584,http://twitter.com/chemoadvisor
06/10/14,http://twitter.com/chemoadvisor/status/476329220634079232,chemoadvisor,#BreastCancer risk appears to be higher after treatment for Hodgkin #lymphoma #bcsm #lymsm http://t.co/HYz1L0WFsj,8.35377,http://twitter.com/ChemoAdvisor/status/476329220634079232,http://twitter.com/chemoadvisor
06/10/14,http://twitter.com/penrynpam/status/476331425579679744,penrynpam,RT @ChemoAdvisor: #BreastCancer risk appears to be higher after treatment for Hodgkin #lymphoma #bcsm #lymsm http://t.co/HYz1L0WFsj,7.3117495,http://twitter.com/PenrynPam/status/476331425579679744,http://twitter.com/penrynpam
06/10/14,http://twitter.com/chemoadvisor/status/476340649349099520,chemoadvisor,What do you think of nivolumab receiving a breakthrough designation for Hodgkin #lymphoma? #lymsm http://t.co/y1eAXs5N4t,7.2194633,http://twitter.com/ChemoAdvisor/status/476340649349099520,http://twitter.com/chemoadvisor
06/10/14,http://twitter.com/mayocancercare/status/476356492967571456,mayocancercare,"RT @MayoClinicLymph: #Research #video: Vitamin D in patients w/ #lymphoma (#DLBCL) strongly assoc. w/ cancer progression, survival. http://…",7.111302,http://twitter.com/MayoCancerCare/status/476356492967571456,http://twitter.com/mayocancercare
06/10/14,http://twitter.com/chemoadvisor/status/476404818849054720,chemoadvisor,Socioeconomic Status Linked to Survival in Diffuse Large B-Cell #Lymphoma #lymsm http://t.co/NGLcWmUVBu,7.3667564,http://twitter.com/ChemoAdvisor/status/476404818849054720,http://twitter.com/chemoadvisor
06/10/14,http://twitter.com/mayocliniclymph/status/476412217995165696,mayocliniclymph,Meet Matt Lampson. Soccer pro and #lymphoma cancer survivor (+playlist): http://t.co/1Yk5yYzqi6 via @YouTube and @LLSusa #lymsm,7.475581,http://twitter.com/MayoClinicLymph/status/476412217995165696,http://twitter.com/mayocliniclymph
06/10/14,http://twitter.com/maurerstats/status/476425037948272640,maurerstats,Event-free survival at 24 months is important milestone for outcome in DLBCL patients treated with R-CHOP #JCO http://t.co/JOlxIFzcOh #lymsm,6.9789467,http://twitter.com/MaurerStats/status/476425037948272640,http://twitter.com/maurerstats
06/11/14,http://twitter.com/maurerstats/status/476565572898279424,maurerstats,RT @mtmdphd: Socioeconomic disparities in mortality after DLBCL in modern treatment era - Tao et al. Blood http://t.co/CkHvefROYM #lymsm,7.134713,http://twitter.com/MaurerStats/status/476565572898279424,http://twitter.com/maurerstats
06/11/14,http://twitter.com/mdandersonnews/status/476707575971721216,mdandersonnews,#Lymphoma survivor becomes mother again five years after #cancer treatment: http://t.co/c698OX4zFM #cancersurvivor #lymsm #endcancer,12.73136,http://twitter.com/MDAndersonNews/status/476707575971721216,http://twitter.com/mdandersonnews
06/11/14,http://twitter.com/castroaleca/status/476707692027731968,castroaleca,RT @MDAndersonNews: #Lymphoma survivor becomes mother again five years after #cancer treatment: http://t.co/c698OX4zFM #cancersurvivor #lym…,7.2316628,http://twitter.com/CastroAleca/status/476707692027731968,http://twitter.com/castroaleca
06/11/14,http://twitter.com/julcecilia/status/476708223769378816,julcecilia,RT @MDAndersonNews: #Lymphoma survivor becomes mother again five years after #cancer treatment: http://t.co/c698OX4zFM #cancersurvivor #lym…,7.2316628,http://twitter.com/JulCecilia/status/476708223769378816,http://twitter.com/julcecilia
06/11/14,http://twitter.com/aurelin15/status/476711743809671168,aurelin15,RT @MDAndersonNews: #Lymphoma survivor becomes mother again five years after #cancer treatment: http://t.co/c698OX4zFM #cancersurvivor #lym…,7.2316628,http://twitter.com/AURELIN15/status/476711743809671168,http://twitter.com/aurelin15
06/11/14,http://twitter.com/onlygirloutof5/status/476723854254301184,onlygirloutof5,RT @MDAndersonNews: #Lymphoma survivor becomes mother again five years after #cancer treatment: http://t.co/c698OX4zFM #cancersurvivor #lym…,7.2316628,http://twitter.com/onlygirloutof5/status/476723854254301184,http://twitter.com/onlygirloutof5
06/11/14,http://twitter.com/curseen/status/476734370418413569,curseen,RT @MDAndersonNews: #Lymphoma survivor becomes mother again five years after #cancer treatment: http://t.co/c698OX4zFM #cancersurvivor #lym…,7.2316628,http://twitter.com/Curseen/status/476734370418413569,http://twitter.com/curseen
06/11/14,http://twitter.com/dawnka/status/476735510736420864,dawnka,RT @MDAndersonNews: #Lymphoma survivor becomes mother again five years after #cancer treatment: http://t.co/c698OX4zFM #cancersurvivor #lym…,10.452206,http://twitter.com/DawnKA/status/476735510736420864,http://twitter.com/dawnka
06/11/14,http://twitter.com/subatomicdoc/status/476748225098285057,subatomicdoc,There Are No Guarantees http://t.co/PDpzou88Bn &gt;@DrMarkham #lymsm #gyncsm #hcsm,11.921146,http://twitter.com/subatomicdoc/status/476748225098285057,http://twitter.com/subatomicdoc
06/11/14,http://twitter.com/shewithlynch/status/476749255164440577,shewithlynch,RT @subatomicdoc: There Are No Guarantees http://t.co/PDpzou88Bn &gt;@DrMarkham #lymsm #gyncsm #hcsm,7.306795,http://twitter.com/ShewithLynch/status/476749255164440577,http://twitter.com/shewithlynch
06/11/14,http://twitter.com/gerrywieder/status/476752191999717376,gerrywieder,RT @subatomicdoc: There Are No Guarantees http://t.co/PDpzou88Bn &gt;@DrMarkham #lymsm #gyncsm #hcsm,10.478236,http://twitter.com/GerryWieder/status/476752191999717376,http://twitter.com/gerrywieder
06/12/14,http://twitter.com/mdaprotons/status/477087850635083777,mdaprotons,#Lymphoma survivor becomes mother again 5 years after #protontherapy treatment: http://t.co/qKnxB00Onc via @MDAndersonNews #lymsm #endcancer,10.446029,http://twitter.com/MDAProtons/status/477087850635083777,http://twitter.com/mdaprotons
06/14/14,http://twitter.com/maurerstats/status/477618966110539776,maurerstats,Welcome to twitter @MayoClinicCLL #lymsm,9.126215,http://twitter.com/MaurerStats/status/477618966110539776,http://twitter.com/maurerstats
06/16/14,http://twitter.com/chemoadvisor/status/478573978240679937,chemoadvisor,Time to Progression Worse in Nodular Lymphocyte-predominant #HodgkinLymphoma #lymsm http://t.co/gJhYsRmnZh,7.2250333,http://twitter.com/ChemoAdvisor/status/478573978240679937,http://twitter.com/chemoadvisor
06/17/14,http://twitter.com/mayocliniclymph/status/478890253025955840,mayocliniclymph,"Learn more about ""Biological therapy or immunotherapy for non-Hodgkin lymphoma"" from @AmericanCancer Society | http://t.co/1v5kJRWZC2 #lymsm",7.1929293,http://twitter.com/MayoClinicLymph/status/478890253025955840,http://twitter.com/mayocliniclymph
06/17/14,http://twitter.com/maurerstats/status/478890725921144833,maurerstats,MT @MayoClinicLymph Learn more about biological therapy or immunotherapy for #lymphoma via @AmericanCancer | http://t.co/h2v3KHMVUa #lymsm,7.307248,http://twitter.com/MaurerStats/status/478890725921144833,http://twitter.com/maurerstats
06/17/14,http://twitter.com/asco/status/478933716262461440,asco,"""Read Scans Like This, Not That: For a Subtype of Lymphoma, Scans Predict Survival” http://t.co/0ak8HfIFBX #lymsm #JCO #ASCOconnection",11.322038,http://twitter.com/ASCO/status/478933716262461440,http://twitter.com/asco
06/17/14,http://twitter.com/sherylmcintire/status/478934781783056385,sherylmcintire,"RT @ASCO: ""Read Scans Like This, Not That: For a Subtype of Lymphoma, Scans Predict Survival” http://t.co/0ak8HfIFBX #lymsm #JCO #ASCOconne…",7.1670775,http://twitter.com/SherylMcIntire/status/478934781783056385,http://twitter.com/sherylmcintire
06/17/14,http://twitter.com/maurerstats/status/478942287624302593,maurerstats,MT @ASCO Using Deauville Scale for scans in primary mediastinal B-cell #Lymphoma  http://t.co/5GekkXcF1J  #lymsm #JCO #ASCOconnection,6.870934,http://twitter.com/MaurerStats/status/478942287624302593,http://twitter.com/maurerstats
06/17/14,http://twitter.com/maurerstats/status/478965253586165760,maurerstats,Meta-analysis of methods for determining cell of original in DLBCL - Clinical Lymphoma Myeloma and Leukemia http://t.co/LkJSUqORbd #lymsm,6.982174,http://twitter.com/MaurerStats/status/478965253586165760,http://twitter.com/maurerstats
06/17/14,http://twitter.com/mtmdphd/status/478993376441028608,mtmdphd,Mature Results of a Ph2 Rituximab for Nodular Lymphocyte–Predominant Hodgkin Lymphoma - Advani et al. #JCO http://t.co/sT0xHXe1bu #lymsm,9.924258,http://twitter.com/mtmdphd/status/478993376441028608,http://twitter.com/mtmdphd
06/18/14,http://twitter.com/maurerstats/status/479099247602569216,maurerstats,MT @timfenske ALK-neg ALCL is genetically heterogeneous with widely disparate  outcomes.  Blood  http://t.co/6804SsObGI #lymsm,6.9486794,http://twitter.com/MaurerStats/status/479099247602569216,http://twitter.com/maurerstats
06/18/14,http://twitter.com/maurerstats/status/479103587461513220,maurerstats,MT @OncLive: Experts Discuss Combination Therapy in Large Cell #Lymphoma http://t.co/fOMtX9eD0p #lymsm,7.589267,http://twitter.com/MaurerStats/status/479103587461513220,http://twitter.com/maurerstats
06/18/14,http://twitter.com/mtmdphd/status/479261347281391616,mtmdphd,IPI24:  An IPI For EFS24 Endpoint For DLBCL In The Immunochemotherapy Era - @MauerStats et al. #ASH13 http://t.co/pzcRyTAHRe #lymsm,9.873195,http://twitter.com/mtmdphd/status/479261347281391616,http://twitter.com/mtmdphd
06/18/14,http://twitter.com/mtmdphd/status/479274715240882176,mtmdphd,Rituximab Therapy for Nodular Lymphocyte–Predominant Hodgkin Lymphoma (NLPHL) - Advani et al. #JCO http://t.co/2bYmdu6NWM #lymsm,11.295946,http://twitter.com/mtmdphd/status/479274715240882176,http://twitter.com/mtmdphd
06/18/14,http://twitter.com/drzafergokgoz/status/479275963369676801,drzafergokgoz,RT @mtmdphd: Rituximab Therapy for Nodular Lymphocyte–Predominant Hodgkin Lymphoma (NLPHL) - Advani et al. #JCO http://t.co/2bYmdu6NWM #lym…,6.540947,http://twitter.com/drzafergokgoz/status/479275963369676801,http://twitter.com/drzafergokgoz
06/18/14,http://twitter.com/pscgi/status/479280906612768768,pscgi,RT @mtmdphd: Rituximab Therapy for Nodular Lymphocyte–Predominant Hodgkin Lymphoma (NLPHL) - Advani et al. #JCO http://t.co/2bYmdu6NWM #lym…,6.540947,http://twitter.com/PSCGI/status/479280906612768768,http://twitter.com/pscgi
06/18/14,http://twitter.com/naiemissa/status/479282177386242048,naiemissa,RT @mtmdphd: Rituximab Therapy for Nodular Lymphocyte–Predominant Hodgkin Lymphoma (NLPHL) - Advani et al. #JCO http://t.co/2bYmdu6NWM #lym…,6.540947,http://twitter.com/naiemissa/status/479282177386242048,http://twitter.com/naiemissa
06/18/14,http://twitter.com/maurerstats/status/479323490856603648,maurerstats,MT @MayoCancerCare Harnessing the immune system to fight #lymphoma: http://t.co/8HKAt5nsQR  #cimchat #lymsm @MayoClinicLymph,8.844186,http://twitter.com/MaurerStats/status/479323490856603648,http://twitter.com/maurerstats
06/18/14,http://twitter.com/aamdevera/status/479323718053670912,aamdevera,RT @MaurerStats: MT @MayoCancerCare Harnessing the immune system to fight #lymphoma: http://t.co/8HKAt5nsQR  #cimchat #lymsm @MayoClinicLym…,7.0289116,http://twitter.com/aamdevera/status/479323718053670912,http://twitter.com/aamdevera
06/18/14,http://twitter.com/maurerstats/status/479324210020376576,maurerstats,EFS24 in diffuse large B-cell #lymphoma http://t.co/IJUwgdXUMo via @YouTube #lymsm,7.3988605,http://twitter.com/MaurerStats/status/479324210020376576,http://twitter.com/maurerstats
06/18/14,http://twitter.com/mayocliniclymph/status/479326478903934979,mayocliniclymph,MT @MayoCancerCare Harnessing the immune system to fight lymphoma: http://t.co/RvDOvGeQh1  #CIMchat #lymsm,7.3653703,http://twitter.com/MayoClinicLymph/status/479326478903934979,http://twitter.com/mayocliniclymph
06/18/14,http://twitter.com/drmarkham/status/479405737756852225,drmarkham,"From @ASCOPost, Looking Ahead in Treating CLL http://t.co/RxgBsy3J3M #lymsm",12.378986,http://twitter.com/DrMarkham/status/479405737756852225,http://twitter.com/drmarkham
06/19/14,http://twitter.com/asco/status/479422260688998400,asco,"RT @DrMarkham: From @ASCOPost, Looking Ahead in Treating CLL http://t.co/RxgBsy3J3M #lymsm",10.931797,http://twitter.com/ASCO/status/479422260688998400,http://twitter.com/asco
06/19/14,http://twitter.com/sherylmcintire/status/479424950386700288,sherylmcintire,"RT @DrMarkham: From @ASCOPost, Looking Ahead in Treating CLL http://t.co/RxgBsy3J3M #lymsm",7.5931287,http://twitter.com/SherylMcIntire/status/479424950386700288,http://twitter.com/sherylmcintire
06/19/14,http://twitter.com/chemoadvisor/status/479698938388561920,chemoadvisor,Elderly Men May Need Higher Rituximab Dose for Diffuse Large B-Cell #Lymphoma #lymsm http://t.co/zH4QQ194NK,7.2179914,http://twitter.com/ChemoAdvisor/status/479698938388561920,http://twitter.com/chemoadvisor
06/19/14,http://twitter.com/chemoadvisor/status/479713574609104898,chemoadvisor,Looking for info on #lymphoma? Check out our Lymphoma Resource Center #lymsm http://t.co/BdbGfdIHt3,7.530814,http://twitter.com/ChemoAdvisor/status/479713574609104898,http://twitter.com/chemoadvisor
06/19/14,http://twitter.com/mayocliniclymph/status/479734453875384320,mayocliniclymph,Another way to connect with each other: Mayo Clinic Connect - http://t.co/Qy8lRH8sOV #lymsm,7.6529493,http://twitter.com/MayoClinicLymph/status/479734453875384320,http://twitter.com/mayocliniclymph
06/19/14,http://twitter.com/drmiguelperales/status/479734469071732737,drmiguelperales,#BMTCTN P Stiff discussing @SWOG trial Tandem AutoSCT in Pts w Progressive or Recurrent #Hodgkin Lymphoma http://t.co/5DJnykeFdw #lymsm,6.91428,http://twitter.com/DrMiguelPerales/status/479734469071732737,http://twitter.com/drmiguelperales
06/19/14,http://twitter.com/chemoadvisor/status/479761871063777280,chemoadvisor,Rituximab doses may be too low for elderly men with diffuse large b-cell #lymphoma #lymsm http://t.co/tOgOGtPA0Q,8.779033,http://twitter.com/ChemoAdvisor/status/479761871063777280,http://twitter.com/chemoadvisor
06/20/14,http://twitter.com/pharmlogsx/status/479789781199495170,pharmlogsx,RT @ChemoAdvisor: Rituximab doses may be too low for elderly men with diffuse large b-cell #lymphoma #lymsm http://t.co/tOgOGtPA0Q,7.011854,http://twitter.com/pharmlogsx/status/479789781199495170,http://twitter.com/pharmlogsx
06/20/14,http://twitter.com/drcbsteer/status/480106872251224064,drcbsteer,B-Cell Lymphoma Rituximab Dose May Be Too Low in Elderly Men #lymsm http://t.co/QibW1o4df7,7.4450793,http://twitter.com/drcbsteer/status/480106872251224064,http://twitter.com/drcbsteer
06/21/14,http://twitter.com/chemoadvisor/status/480466474373750785,chemoadvisor,MRI catches #breastcancer early in Hodgkin #lymphoma survivors #lymsm http://t.co/y9IrzaeP0P,9.140005,http://twitter.com/ChemoAdvisor/status/480466474373750785,http://twitter.com/chemoadvisor
06/21/14,http://twitter.com/crystaleitnier/status/480477020384935937,crystaleitnier,RT @ChemoAdvisor: MRI catches #breastcancer early in Hodgkin #lymphoma survivors #lymsm http://t.co/y9IrzaeP0P,7.3713937,http://twitter.com/CrystalEitnier/status/480477020384935937,http://twitter.com/crystaleitnier
06/22/14,http://twitter.com/chemoadvisor/status/480698010637463553,chemoadvisor,CNS involvement risk is higher in patients with #AIDS-related #lymphoma #lymsm http://t.co/2CT4wmWnL6,8.3995905,http://twitter.com/ChemoAdvisor/status/480698010637463553,http://twitter.com/chemoadvisor
06/22/14,http://twitter.com/motownsound_/status/480699830180671491,motownsound_,RT @ChemoAdvisor: CNS involvement risk is higher in patients with #AIDS-related #lymphoma #lymsm http://t.co/2CT4wmWnL6,7.3988605,http://twitter.com/motownsound_/status/480699830180671491,http://twitter.com/motownsound_
06/22/14,http://twitter.com/chemoadvisor/status/480745866576543745,chemoadvisor,Subcutaneous vs. IV administration of rituximab in #lymphoma #lymsm http://t.co/rcRZinI6so,7.6307225,http://twitter.com/ChemoAdvisor/status/480745866576543745,http://twitter.com/chemoadvisor
06/23/14,http://twitter.com/drmiguelperales/status/480904523985084416,drmiguelperales,AlloHCT for Patients Age ≥40 with Non-Hodgkin #Lymphoma: Encouraging PFS McClune et. al @CIBMTR #BBMT #lymsm #bmtsm http://t.co/NXMbUuM3xd,6.670992,http://twitter.com/DrMiguelPerales/status/480904523985084416,http://twitter.com/drmiguelperales
06/23/14,http://twitter.com/chemoadvisor/status/481105781186908160,chemoadvisor,Mogamulizumab offers hope for relapsed T-cell #lymphoma #lymsm http://t.co/Hfy9kJ94it,7.333681,http://twitter.com/ChemoAdvisor/status/481105781186908160,http://twitter.com/chemoadvisor
06/23/14,http://twitter.com/mtmdphd/status/481161592575250432,mtmdphd,CD19 Inhibitor Shows Promise in Non-Hodgkin Lymphoma http://t.co/wuKkYCaZdq #lymsm MT @CancerNetwrk,11.393945,http://twitter.com/mtmdphd/status/481161592575250432,http://twitter.com/mtmdphd
06/23/14,http://twitter.com/natedahlpharmd/status/481168752466087936,natedahlpharmd,RT @mtmdphd: CD19 Inhibitor Shows Promise in Non-Hodgkin Lymphoma http://t.co/wuKkYCaZdq #lymsm MT @CancerNetwrk,6.973062,http://twitter.com/NateDahlPharmD/status/481168752466087936,http://twitter.com/natedahlpharmd
06/24/14,http://twitter.com/lymphomahub/status/481349440847233024,lymphomahub,RT @mtmdphd: CD19 Inhibitor Shows Promise in Non-Hodgkin Lymphoma http://t.co/wuKkYCaZdq #lymsm MT @CancerNetwrk,6.973062,http://twitter.com/lymphomahub/status/481349440847233024,http://twitter.com/lymphomahub
06/24/14,http://twitter.com/maurerstats/status/481427755054006273,maurerstats,MT @nbferrara Mayo Clinic Cancer Center has a new Twitter feed! Follow @MayoCancerCare for cancer info&amp;news from #MayoClinic. #lymsm #gyncsm,6.9189153,http://twitter.com/MaurerStats/status/481427755054006273,http://twitter.com/maurerstats
06/25/14,http://twitter.com/maurerstats/status/481791377530179586,maurerstats,MT @ASCOPost: Video Report From #ASCO14 with Drs Armitage and Pfreundschuh on Diffuse Large B-Cell #Lymphoma http://t.co/y41mPa7aog #lymsm,6.940675,http://twitter.com/MaurerStats/status/481791377530179586,http://twitter.com/maurerstats
06/25/14,http://twitter.com/mtmdphd/status/481836812374384640,mtmdphd,IPI24:  An IPI For EFS24 Endpoint For DLBCL In The Immunochemotherapy Era - @MauerStats et al. #ASH13 http://t.co/wxAaoRKaRY #lymsm,10.626271,http://twitter.com/mtmdphd/status/481836812374384640,http://twitter.com/mtmdphd
06/25/14,http://twitter.com/ayeshaarshadaa/status/481843278271512577,ayeshaarshadaa,RT @mtmdphd: IPI24:  An IPI For EFS24 Endpoint For DLBCL In The Immunochemotherapy Era - @MauerStats et al. #ASH13 http://t.co/wxAaoRKaRY #…,6.6475167,http://twitter.com/ayeshaarshadaa/status/481843278271512577,http://twitter.com/ayeshaarshadaa
06/26/14,http://twitter.com/sethbla/status/482235676227018752,sethbla,RT @ChemoAdvisor: MRI catches #breastcancer early in Hodgkin #lymphoma survivors #lymsm http://t.co/yHgdpl72RI,8.999446,http://twitter.com/SethBla/status/482235676227018752,http://twitter.com/sethbla
06/26/14,http://twitter.com/penrynpam/status/482237695423696896,penrynpam,RT @SethBla: RT @ChemoAdvisor: MRI catches #breastcancer early in Hodgkin #lymphoma survivors #lymsm http://t.co/yHgdpl72RI,7.185534,http://twitter.com/PenrynPam/status/482237695423696896,http://twitter.com/penrynpam
06/26/14,http://twitter.com/maurerstats/status/482262276397752320,maurerstats,Mayo Clinic Recommends New Routine Testing for some T-cell Non-Hodgkin Lymphomas http://t.co/hTWXJKQ81t #lymsm,7.13302,http://twitter.com/MaurerStats/status/482262276397752320,http://twitter.com/maurerstats
06/26/14,http://twitter.com/maurerstats/status/482264076194549760,maurerstats,Discussion by Mayo pathologist Dr. Andy Feldman of our ALCL genetics study | Blood https://t.co/Eg3PEniZ4c http://t.co/bdu7A8n5nL #lymsm,8.314636,http://twitter.com/MaurerStats/status/482264076194549760,http://twitter.com/maurerstats
06/26/14,http://twitter.com/mayocliniclymph/status/482273903138451456,mayocliniclymph,RT @MaurerStats: Discussion by Mayo pathologist Dr. Andy Feldman of our ALCL genetics study | Blood https://t.co/Eg3PEniZ4c http://t.co/bdu…,7.2179914,http://twitter.com/MayoClinicLymph/status/482273903138451456,http://twitter.com/mayocliniclymph
06/26/14,http://twitter.com/mayocliniclymph/status/482278254871453697,mayocliniclymph,MT @MayoClinic Mayo Clinic Recommends New Routine Testing for some #NonHodgkin #Lymphomas http://t.co/VEG0I9tF5H  #lymsm,7.2619,http://twitter.com/MayoClinicLymph/status/482278254871453697,http://twitter.com/mayocliniclymph
06/27/14,http://twitter.com/chemoadvisor/status/482539489316073472,chemoadvisor,Proton Therapy May Be Safe for Hodgkin #Lymphoma #lymsm http://t.co/EzAEIizG2N,7.796953,http://twitter.com/ChemoAdvisor/status/482539489316073472,http://twitter.com/chemoadvisor
06/27/14,http://twitter.com/ferrerdehdz/status/482542558112137217,ferrerdehdz,"#Health&amp;Cancer ""@ChemoAdvisor: Proton Therapy May Be Safe for Hodgkin #Lymphoma #lymsm http://t.co/QPwgAbbSTC""",10.71422,http://twitter.com/ferrerdehdz/status/482542558112137217,http://twitter.com/ferrerdehdz
06/28/14,http://twitter.com/mtmdphd/status/482874918695350272,mtmdphd,CD19 Inhibitor Shows Promise in Non-Hodgkin Lymphoma http://t.co/6WPz8xB6WM #lymsm MT @CancerNetwrk,11.000564,http://twitter.com/mtmdphd/status/482874918695350272,http://twitter.com/mtmdphd
06/28/14,http://twitter.com/graghirardi/status/482875914548961281,graghirardi,RT @mtmdphd: CD19 Inhibitor Shows Promise in Non-Hodgkin Lymphoma http://t.co/6WPz8xB6WM #lymsm MT @CancerNetwrk,6.999948,http://twitter.com/GraGhirardi/status/482875914548961281,http://twitter.com/graghirardi
06/29/14,http://twitter.com/chemoadvisor/status/483339315473547264,chemoadvisor,An oral arsenic-based regimen may harbor benefits for patients with relapsed/refractory mantle cell #lymphoma #lymsm http://t.co/MS6ux3Crjh,6.999948,http://twitter.com/ChemoAdvisor/status/483339315473547264,http://twitter.com/chemoadvisor
06/30/14,http://twitter.com/chemoadvisor/status/483642569327640576,chemoadvisor,Find the latest news in #lymphoma here! #lymsm http://t.co/EXbFzEr6BQ,8.158415,http://twitter.com/ChemoAdvisor/status/483642569327640576,http://twitter.com/chemoadvisor
